· Web viewOzyar E, Selek U, Laskar S, Uzel O, Anacak Y, Ben-Arush M, Polychronopoulou S, Akman F,...

Curriculum VitaeRobert Clell Miller, MD

Professor, Department of Radiation OncologyUniversity of Maryland School of Medicine

Date: April 3, 2019

Contact Information

Business Address: Department of Radiation Oncology, Maryland Proton Treatment Center850 W. Baltmore St., 3rd FlBaltimore, MD 21201

Business Phone number: 410-369-5200Fax Number: 410-347-0870Email: [email protected]

Education

1981-1983 Oklahoma State University1983-1985 B.S. in Business Administration (cum laude), University of Tulsa1985-1987 B.S. in Engineering Physics, University of Tulsa1987-1990 M.S. in Radiological Medical Physics, honors, University of Kentucky1989-1993 M.D., with distinction, University of Kentucky2011-2013 MBA, Oxford University, Oxford, U.K.

Post Graduate Education and Training

1993-1994 Internship, Department of Internal Medicine, University of Kentucky1994-1998 Residency, Department of Radiation Oncology, Mayo Clinic, Rochester, MN

Certifications

1998 American Board of Radiology

Medical Licensures

1994 Active, Minnesota2014 Active, Florida2015 Inactive, Georgia1996 Inactive, Mississippi1996 Inactive, Alabama1996 Inactive, Kentucky1996 Inactive, Tennessee1997 Inactive, Wisconsin

Employment History

Robert C. Miller, MD 1 | P a g e

mailto:[email protected]

Academic Appointment

Mayo Clinic, Rochester, Minnesota1998-2002 Instructor, Radiation Oncology, Mayo Clinic School of Medicine2002-2009 Assistant Professor, Radiation Oncology, Mayo Clinic School of Medicine2009-2011 Associate Professor, Radiation Oncology, Mayo Clinic School of Medicine2011-2014 Professor, Radiation Oncology, Mayo Clinic School of Medicine

Mayo Clinic, Jacksonville, Florida2014-2019 Professor, Radiation Oncology, Mayo Clinic School of Medicine

University of Maryland School of Medicine2019-present Professor, Radiation Oncology, UMSOM

Professional Society Membership

1998-2019present General Member & Fellow, American Society for Radiation Oncology (ASTRO)1999-2019present General Member, American Society for Clinical Oncology (ASCO)

Honors and Awards

1990 Exceptional Summer Student Award, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD

1996-1997 The Davenport Fellowship in Radiation Oncology, Mayo Clinic, Rochester, Minnesota1997 Resident Clinical/Basic Research Award, American Society of Therapeutic

Radiologists and Oncologists1997 Young Oncologist Essay Award in Radiation Oncology, American Radium Society1998 RSNA Roentgen Resident/Fellow Research Award2002 Fellow, Royal Society of Arts, London, UK2014 Mayo School of Health Sciences Outstanding Physician/Scientist Award2015 Fellow, Royal Society of Medicine, London, UK2015 Fellow, American Society for Radiation Oncology (ASTRO)

Clinical Activities

Clinical Expertise

Board certified radiation oncologist with expertise in the treatment of gastrointestinal, hematological, and thoracic malignanciesExperienced in the use of IMRT, IGRT, brachytherapy for GI malignancies, stereotactic body radiotherapy for lung, GI, and liver metastases, IORT for pelvic malignancies, proton radiotherapy, and radio-isotope therapyResearch focus in patient reported outcomes and clinical trials evaluating drugs to ameliorate radiotherapy and chemotherapy toxicity

Scope of Clinical Practice

1998-2001 Mayo Clinic Health System Mankato Hospital


Radiation Oncology Clinic 200+ new patients per yearAttending physician100% FTEOversaw introduction of 3D Radiotherapy treatments and led re-accreditation of the Commission on Cancer Certification

2001-2014 Mayo Clinic RochesterDepartment of Radiation Oncology200+ new patients a yearAttending physician, Vice Chair for Regional Practice from 2006-2013 leading a five radiotherapy center regional network and Vice Chair for Research 2013-2014 developing clinical trials for proton beam radiotherapyOversaw introduction of IMRT regional practices outside Rochester, Minnesota. Participated in the development of the Rochester Mayo Clinic proton beam therapy program. 100% FTE

2014-present Mayo Clinic Florida Department of Radiation Oncology 250+ new patients a year Attending physician, Vice Chair for Research 2014-2019 Oversaw opening of Mayo Clinic Regional Radiotherapy practice in Waycross, Georgia. Leading development of the Mayo Clinic Florida Center for Integrated Oncological Care, a >$230 million dollar capital expansion project introducing proton radiotherapy and MR LINAC technology to the Mayo Clinic Florida campus.100%

Administrative Service

Institutional Service

Mayo Clinic Health System Mankato 1999-2001 Chair, Cancer Committee 1999-2001 Hospital Liaison, American College of Surgeons' Commission on Cancer 1999-2001 Member, Institutional Review Board & Quality Improvement Committee 2000 Interim Chair, Institutional Review Board & Quality Improvement Committee 2000 Member, Hospital Strategy Group

Mayo Clinic, Rochester, Minnesota

2002-2005 Ethics Consultation Service2002-2007 Chair, Quality Performance Improvement Committee, Department of Radiation

Oncology 2002-2014 Clinical Practice Executive Committee, Department of Radiation Oncology 2005-2010 Charged Particle Facility Committee, Department of Radiation Oncology - Led research

infrastructure development and participated in facility development for the Mayo Clinic Rochester proton therapy program.


2006-2014 Vice Chair, Radiation Oncology Executive Committee - Successfully led operations, practice convergence and growth of the Mayo Clinic Radiation Oncology Regional Practice system in the Midwest (annual revenues $32 million USD), including design and construction of a $12 million USD freestanding radiation oncology center on the St. Olaf College campus as a joint venture between Mayo Clinic and St. Olaf.

2009-2012 Board of Trustees, Albert Lea Medical Center-Mayo Clinic Health System2009-2012 Chair, Board of Trustees Compensation Committee, Albert Lea Medical Center-Mayo

Clinic Health System 2010-2012 Treasurer, Board of Trustees Finance Committee, Albert Lea Medical Center-Mayo

Clinic Health System 2010-2014 Proton Beam Therapy Center Steering Committee, Department of Radiation Oncology2012-2014 Carbon Ion Radiotherapy Planning Committee, Department of Radiation Oncology -

Participated in development of a carbon ion radiotherapy facility plan for Mayo Clinci.2013-2014 Member, Cancer Center Clinical Trials Subcommittee 2013-2016 Vice Chair, Board of Trustees, Mayo Clinic Health System Albert Lea-Austin - Board of

Trustees for a rural medical system with approximately 3,000 employees and $200 million dollars annual turnover.

2014-2015 Minnesota Physicians Service Agreement Negotiations Team, Mayo Clinic Health System Southeast Minnesota Region Administration, Northfield, - Successfully negiotated transfer of an 18 provider physician services agreement for primary care providers to Northfield Hospital and Clinics.

2014-2016 Midwest I-35 Strategy Group, Mayo Clinic Health System Southeast Minnesota Region Administration

2014-2016 Medical Director, Mayo Clinic Health System Southeast Minnesota Regional Administration, Northfield, Minnesota - Led strategy development and implementation for expansion of community specialty services in the Northfield and Lakeville, Minnesota region. Played a negotiation role between Mayo Clinic Health System senior leadership and Board of Trustees and the management team of Northfield Hospital and Clinics, physicians in Mayo Clinic’s PSA agreement with NH&C, independent community physicians, community leaders, St. Olaf College, Carleton University, and executive leaders in the Mayo Clinic Health System’s Southwestern region and Cannon Falls/Red Wing area.

2016 Chair, Mayo Clinic Health System Southeast Minnesota Regional Administration, Southern Minneapolis-St. Paul Metropolitan region strategic planning group, – Led strategy development for implementation of community based specialty services in the south Twin Cities Metro region of Minnesota.

Mayo Clinic, Jacksonville, Florida

2016-present Vice Chair, Mayo Clinic Cancer Center Clinical Practice Committee - The Mayo Clinic Cancer Center - Practice Committee coordinates cancer care delivery and resources across the Mayo Clinic enterprise in Minnesota, Florida, Arizona, Wisconsin, and Iowa. The committee is accountable for practice standardization, patient access, overall payer mix, staffing models, care delivery, practice quality, clinical trial availability and implementation, disease group practice oversight and recruitment in collaboration with site and department leadership.


2018-present Medical Director, Mayo Clinic Florida Particle Therapy program - Successfully led the development and planning of the Mayo Clinic Florida Center for Integrated Oncological Care (>230 million USD capital project).

Local and National Service

National Service

2001-present Ad hoc reviewer for 37 journals2005-2008 Editorial Board Member, Diseases of the Esophagus2007-2010 Member, Evolving Technology Committee Evaluation Subcommittee, American Society

for Radiation Oncology 2008-2014 Chair, Membership Committee, American Society for Radiation Oncology 2011-2013 Chair, Membership committee, American Society for Radiation Oncology 2008-2019 Annual Scientific Meeting Abstract Review Sub-Committees, American Society for

Radiation Oncology, 2009-2015 Editor in Chief, Rare Tumors, Pagepress Publications2011-2013 Member, Workforce Survey Subcommittee, American Society for Radiation Oncology 2011-2013 Member, International Education Committee Task force, American Society for

Radiation Oncology 2012-2016 Member, Communications Committee of the Education Council, American Society for

Radiation Oncology 2014-present Member, State Captain Initiative, American Society for Radiation Oncology 2014-present Member, Research Committee, Radiation Oncology Institute 2018-present Vice Chair, Research Committee, Radiation Oncology Research Institute 2015-present Task Group No. 263 - Standardizing Nomenclature - for Radiation Therapy, American

Association of Physicists in Medicine2015-present Editor in Chief, ASTRO’s Advances in Radiation Oncology, American Society for

Radiation Oncology2018-present Chair, Annual Scientific Meeting Bioinformatics Track, American Society for Radiation

Oncology 2019-present Chair, Annual Scientific Meeting History, Education, and Social Media, American Society

for Radiation Oncology

Teaching Service

Undergraduate Student Teaching

2015-2018 Clinical Research Program Mentor, Mentor Summer Research Training Program, Mayo Clinic3-4 undergraduates, daily contact for the summer

Resident and Fellow Teaching

2001-2014 Lecturer, GI Malignances and Radiation Oncology 10-20, Radiation Oncology residents and fellows - 60 contact hours/year

2001-2014 Lecturesr, Hematological Malignances and Radiation Oncology 10-20, Radiation Oncology residents and fellows - 20 contact hours/year


2001-2014 Lecturer, Thoracic Malignances and Radiation Oncology 10-20, Radiation Oncology residents and fellows - 20 contact hours/year

2014-present Lecturer, GI Malignances and Radiation Oncology1-3, Radiation Oncology residents - 6 contact hours/year

Post-Graduate Teaching

2015-2016 Research Mentor1 post-graduate, 5 hours/week

Grant Support

Completed Grants:

2011-2013 (PI: 100%)Translational Biology of Pseudomyxoma Peritonei (PMP)National Organization of Rare Disease, NORD-01.Annual Direct Costs: $11,000

Total Direct Costs: $33,0002012-2015 (PI: 100%)

A pilot study of lisinopril on pulmonary distress in patients receiving radiotherapyNational Cancer Institute, CA 37447Annual Direct Costs: ≈$20,000Total Direct Costs: $66,000

2012-2014 (Co-PI: 5%; PI: L. Travis)Genetic Susceptibility and Biomarkers of Platinum-related ToxicitiesNational Cancer Institute, R01 CA157823Annual Direct Costs: ≈$20,000Total Direct Costs: $53,000Co-PI for Mayo Clinic in creating a survivorship cohort for testicular cancer survivors for genetic characterizations of late effects of therapy.

2013-2015 (PI: 100%)MC13C1, A Pilot, Double-blind, Randomized, Two-arm Crossover Study of DoxepinVersus Placebo for Esophagitis-induced Pain in Patients Receiving Radiotherapy to theThorax with or without Chemotherapy. National Cancer Institute, CA 37447 Annual Direct Costs: ≈$33,000Total Direct Costs: $66,000

2015 (PI: 100%)Mayo Clinic Florida Cancer Focused Research Team grant“A prospective radiogenomics registry for validating predictive models and biomarkers of radiotherapy toxicity in the REQUITE study”Total Direct Cost: $40,000

Publications

Peer reviewed journal articles


1. Urano M, Majima H, Miller R, Kahn J. Cytotoxic effect of 1,3 bis (2-chloroethyl)-N-nitrosourea at elevated temperatures: Arrhenius plot analysis and tumour response. Int J Hyperthermia. 1991 May-Jun; 7(3):499-510. PMID: 1919145

2. Miller RC, Wilson KG, Feola JM, Urano M, Yaes RJ, McLaughlin P, Maruyama Y. Megavoltage grid total body irradiation of C3Hf/SED mice. Strahlenther Onkol. 1992 Jul; 168(7):423-6. PMID: 1496454

3. Miller RC, Foote RL, Coffey RJ, Gorman DA, Earle JD, Schomberg PJ, Kline RW. The role of stereotactic radiosurgery in the treatment of malignant skull base tumors. Int J Radiat Oncol Biol Phys. 1997 Dec 1; 39(5):977-81. PMID: 9392534

4. Miller RC, Bonner JA, Wenger DE, Foote RL, Kisrow KL, Shaw EG. Spinal cord localization in the treatment of lung cancer: use of radiographic landmarks. Int J Radiat Oncol Biol Phys. 1998 Jan 15; 40: (2)347-51. PMID: 9457820

5. Miller RC, Martenson JA, Sargent DJ, Kahn MJ, Krook JE. Acute treatment-related diarrhea during postoperative adjuvant therapy for high-risk rectal carcinoma. Int J Radiat Oncol Biol Phys. 1998 Jun 1; 41(3):593-8. PMID: 9635707

6. Miller RC, Bonner JA, Kline RW. Impact of beam energy and field margin on penumbra at lung tumor-lung parenchyma interfaces. Int J Radiat Oncol Biol Phys. 1998 Jun 1; 41(3):707-13. PMID: 9635723

7. Miller RC, Foote RL, Coffey RJ, Sargent DJ, Gorman DA, Schomberg PJ, Kline RW. Decrease in cranial nerve complications after radiosurgery for acoustic neuromas: a prospective study of dose and volume. Int J Radiat Oncol Biol Phys. 1999 Jan 15; 43(2):305-11. PMID: 10030254

8. Miller RC, Sargent DJ, Martenson JA, MacDonald JS, Haller D, Mayer RJ, Gunderson LL, Rich TA, Cha SS, O'Connell MJ. Acute diarrhea during adjuvant therapy for rectal cancer: A detailed analysis from a randomized intergroup trial. Int J Radiat Oncol Biol Phys. 2002 Oct 1; 54(2):409-13. PMID: 12243815

9. Gold DG, Miller RC. Metastatic thymoma: A case report of an isolated, intra-abdominal metastasis causing asymptomatic spinal cord compression. Radiother Oncol. 2005; 39(2):141-6, 164. PMID: 0

10. Brown PD, Foote RL, McLaughlin MP, Halyard MY, Ballman KV, Collie AC, Miller RC, Flemming KD, Hallett JW. A historical prospective cohort study of carotid artery stenosis after radiotherapy for head and neck malignancies. Int J Radiat Oncol Biol Phys. 2005 Dec 01; 63: (5)1361-7. PMID: 16169673 DOI: 10.1016/j.ijrobp.2005.05.046

11. McKian KP, Miller RC, Cassivi SD, Jatoi A. Curing patients with locally advanced esophageal cancer: an update on multimodality therapy. Dis Esophagus. 2006; 19: (6)448-53. PMID: 17069587 DOI: 10.1111/j.1442-2050.2006.00611.x

12. Miller RC, Haddock MG, Gunderson LL, Donohue JH, Trastek VF, Alberts SR, Deschamps C. Intraoperative radiotherapy for treatment of locally advanced and recurrent esophageal and gastric adenocarcinomas. Dis Esophagus. 2006; 19: (6)487-95. PMID: 17069594 DOI: 10.1111/j.1442-2050.2006.00626.x

13. Bhatia S, Miller RC, Lachance DL. Neck extensor muscle weakness (Dropped head syndrome) following radiotherapy. Radiology & Oncology. 2006; 40(1):29-33, 60. PMID: 0

14. Miller RC, Haddock MG, Petersen IA, Gunderson LL, Furth AF. Intraoperative electron-beam radiotherapy and ureteral obstruction. Int J Radiat Oncol Biol Phys. 2006 Mar 1; 64(3):792-8. Epub 2005 Oct 21. PMID: 16243445 DOI: 10.1016/j.ijrobp.2005.08.019

15. Pilepich MV, Paulus R, St Clair W, Brasacchio RA, Rostock R, Miller RC. Phase III study of pentosanpolysulfate (PPS) in treatment of gastrointestinal tract sequelae of radiotherapy. Am J Clin Oncol. 2006 Apr; 29(2):132-7. PMID: 16601430 PMCID: 0 DOI: 10.1097/01.coc.0000203758.77490.fd


16. Monnard V, Sun A, Epelbaum R, Poortmans P, Miller RC, Verschueren T, Scandolaro L, Villa S, Majno SB, Ostermann S, Ozsahin M, Mirimanoff RO. Primary spinal epidural lymphoma: patients' profile, outcome, and prognostic factors: a multicenter Rare Cancer Network study. Int J Radiat Oncol Biol Phys. 2006 Jul 1; 65(3):817-23. Epub 2006 Mar 15. PMID: 16542791 PMCID: 0 DOI: 10.1016/j.ijrobp.2006.01.002

17. Omlin A, Amichetti M, Azria D, Cole BF, Fourneret P, Poortmans P, Naehrig D, Miller RC, Krengli M, Gutierrez Miguelez C, Morgan D, Goldberg H, Scandolaro L, Gastelblum P, Ozsahin M, Dohr D, Christie D, Oppitz U, Abacioglu U, Gruber G. Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network. Lancet Oncol. 2006 Aug; 7(8):652-6. PMID: 16887482 DOI: 10.1016/S1470-2045(06)70765-3

18. Weber DC, Miller RC, Villa S, Hanssens P, Baumert BG, Castadot P, Varlet P, Abacioglu U, Igdem S, Szutowicz E, Nishioka H, Hofer S, Rutz HP, Ozsahin M, Taghian A, Mirimanoff RO. Outcome and prognostic factors in cerebellar glioblastoma multiforme in adults: a retrospective study from the Rare Cancer Network. Int J Radiat Oncol Biol Phys. 2006 Sep 1; 66(1):179-86. Epub 2006 Jul 11. PMID: 16814953 DOI: 10.1016/j.ijrobp.2006.04.035

19. Miller RC, Villa S, Kamer S, Pasquier D, Poortmans P, Micke O, Call TG. Palliative treatment of Erdheim-Chester disease with radiotherapy: a Rare Cancer Network study. Radiother Oncol. 2006 Sep; 80(3):323-6. Epub 2006 Sep 07. PMID: 16959346 DOI: 10.1016/j.radonc.2006.07.034

20. Bhatia S, Miller RC, Haddock MG, Donohue JH, Krishnan S. Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 2006 Oct 1; 66(2):514-9. Epub 2006 Jul 25. PMID: 16863684 DOI: 10.1016/j.ijrobp.2006.04.018

21. Ozyar E, Selek U, Laskar S, Uzel O, Anacak Y, Ben-Arush M, Polychronopoulou S, Akman F, Wolden SL, Sarihan S, Miller RC, Ozsahin M, Abacioglu U, Martin M, Caloglu M, Scandolaro L, Szutowicz E, Atahan IL. Treatment results of 165 pediatric patients with non-metastatic nasopharyngeal carcinoma: a Rare Cancer Network study. Radiother Oncol. 2006 Oct; 81(1):39-46. Epub 2006 Sep 11. PMID: 16965827 DOI: 10.1016/j.radonc.2006.08.019

22. Miller RC, Lachance DH, Lucchinetti CF, Keegan BM, Gavrilova RH, Brown PD, Weinshenker BG, Rodriguez M. Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 2006 Nov 15; 66(4):1178-86. Epub 2006 Sep 11. PMID: 16965867 DOI: 10.1016/j.ijrobp.2006.06.014

23. * Pinn ME, Austin LM, Schomas DA, Miller RC. Case report from Mayo Clinic: Locally advanced Bartholin gland carcinoma. Radiology and Oncology. 2007; 41(2):72-9. PMID: 0

24. McKean H, Miller RC, Jatoi A. Non-traumatic vertebral fractures in patients with locally advanced esophageal cancer: a previously unreported, unrecognized problem. Dis Esophagus. 2007; 20: (2)102-6. PMID: 17439592 DOI: 10.1111/j.1442-2050.2007.00645.x

25. Schallenkamp JM, Miller RC, Brinkmann DH, Foote T, Garces YI. Incidence of radiation pneumonitis after thoracic irradiation: Dose-volume correlates. Int J Radiat Oncol Biol Phys. 2007 Feb 1; 67(2):410-6. PMID: 17236964 DOI: 10.1016/j.ijrobp.2006.09.030

26. Gold DG, Miller RC, Petersen IA, Osborn TG. Radiotherapy for malignancy in patients with scleroderma: The Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 2007 Feb 1; 67(2):559-67. PMID: 17236971 DOI: 10.1016/j.ijrobp.2006.09.003

27. Foote RL, Brown PD, Garces YI, Okuno SH, Miller RC, Strome SE. Informed consent in advanced laryngeal cancer. Head Neck. 2007 Mar; 29(3):230-5. PMID: 17230562

28. Sarkaria JN, Schwingler P, Schild SE, Grogan PT, Mladek AC, Mandrekar SJ, Tan AD, Kobayashi T, Marks RS, Kita H, Miller RC, Limper AH, Leof EB. Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancer. J Thorac Oncol. 2007 Aug; 2(8):751-7. PMID: 17762343 DOI: 10.1097/JTO.0b013e3180cc2587


29. Salama JK, Mell LK, Schomas DA, Miller RC, Devisetty K, Jani AB, Mundt AJ, Roeske JC, Liauw SL, Chmura SJ. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol. 2007 Oct 10; 25(29):4581-6. PMID: 17925552 DOI: 10.1200/JCO.2007.12.0170

30. Gines A, Cassivi SD, Martenson JA Jr, Schleck C, Deschamps C, Sinicrope FA, Alberts SR, Murray JA, Zinsmeister AR, Vazquez-Sequeiros E, Nichols FC 3rd, Miller RC, Quevedo JF, Allen MS, Alexander JA, Zais T, Haddock MG, Romero Y. Impact of endoscopic ultrasonography and physician specialty on the management of patients with esophagus cancer. Dis Esophagus. 2008; 21 (3):241-50 PMID: 18430106 PMCID: 2577373 DOI: 10.1111/j.1442-2050.2007.00766.x

31. Miller R, Iott M, Corsini M. Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS Symposium. Int J Radiat Oncol Biol Phys in press. 2008.

32. Goldberg H, Miller RC, Abdah-Bortnyak R, Steiner M, Yildiz F, Meirovitz A, Villa S, Poortmans PM, Azria D, Zidan J, Ozsahin M, Abacioglu U, Gold DG, Amit A, Lavie O, Atahan IL, Kuten A, Rare Cancer Network. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN). Gynecol Oncol. 2008 Feb; 108(2):298-305. Epub 2007 Dec 21 PMID: 18096209 DOI: 10.1016/j.ygyno.2007.10.037

33. Mell LK, Schomas DA, Salama JK, Devisetty K, Aydogan B, Miller RC, Jani AB, Kindler HL, Mundt AJ, Roeske JC, Chmura SJ. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008 Apr 1; 70(5):1431-7. Epub 2007 Nov 08. PMID: 17996390 DOI: 10.1016/j.ijrobp.2007.08.074

34. Gold DG, Miller RC, Pinn ME, Osborn TG, Petersen IA, Brown PD. Chronic toxicity risk after radiotherapy for patients with systemic sclerosis (systemic scleroderma) or systemic lupus erythematosus: association with connective tissue disorder severity. Radiother Oncol. 2008 Apr; 87(1):127-31. Epub 2007 Dec 26. PMID: 18158195 DOI: 10.1016/j.radonc.2007.11.031

35. Pinn ME, Gold DG, Petersen IA, Osborn TG, Brown PD, Miller RC. Systemic lupus erythematosus, radiotherapy, and the risk of acute and chronic toxicity: the Mayo Clinic Experience. Int J Radiat Oncol Biol Phys. 2008 Jun 1; 71(2):498-506. Epub 2007 Dec 31. PMID: 18164848 DOI: 10.1016/j.ijrobp.2007.10.014

36. Corsini MM, Miller RC, Haddock MG, Donohue JH, Farnell MB, Nagorney DM, Jatoi A, McWilliams RR, Kim GP, Bhatia S, Iott MJ, Gunderson LL. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol. 2008 Jul 20; 26(21):3511-6. PMID: 18640932 DOI: 10.1200/JCO.2007.15.8782

37. Iott MJ, Corsini MM, Miller RC. Evidence-based guidelines for adjuvant therapy for resected adenocarcinoma of the pancreas. Clin J Oncol Nurs. 2008 Aug; 12(4):599-605. PMID: 18676327 DOI: 10.1188/08.CJON.599-605

38. Martenson JA, Halyard MY, Sloan JA, Proulx GM, Miller RC, Deming RL, Dick SJ, Johnson HA, Tai TH, Zhu AW, Keit J, Stien KJ, Atherton PJ. Phase III, double-blind study of depot octreotide versus placebo in the prevention of acute diarrhea in patients receiving pelvic radiation therapy: results of North Central Cancer Treatment Group N00CA. J Clin Oncol. 2008 Nov 10; 26 (32):5248-53 Epub 2008 Sept 02 PMID: 18768432 PMCID: 2652088 DOI: 10.1200/JCO.2008.17.1546

39. Stein ME, Bernstein Z, Abacioglu U, Sengoz M, Miller RC, Meirovitz A, Zouhair A, Freixa SV, Poortmans PH, Ash R, Kuten A. Small cell (neuroendocrine) carcinoma of the prostate: etiology, diagnosis, prognosis, and therapeutic implications--a retrospective study of 30


patients from the rare cancer network. Am J Med Sci. 2008 Dec; 336(6):478-88. PMID: 19092321 DOI: 10.1097/MAJ.0b013e3181731e58

40. * Botros M, Quevedo J, Miller RC. Angiosarcoma of the liver after multimodality therapy for gallbladder carcinoma. Radiology and Oncology. 2009; 43(2):126-31. PMID: 0

41. Nguyen TD, Azria D, Brochonc D, Poortmans P, Miller RC. Cancers de prostate: Quelle place pour la radiotherapie a visee curative chez les patients age? Travail coopératif du Rare Cancer Network (RCN). Cancer Radiothérapie.2009;in press:

42. Jacobs NL, Que FG, Miller RC, Vege SS, Farnell MB, Jatoi A. Cumulative morbidity and late mortality in long-term survivors of exocrine pancreas cancer. J Gastrointest Cancer. 2009; 40 (1-2):46-50 PMID: 19728180 DOI: 10.1007/s12029-009-9082-y

43. Donahue JM, Nichols FC, Li Z, Schomas DA, Allen MS, Cassivi SD, Jatoi A, Miller RC, Wigle DA, Shen KR, Deschamps C. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg. 2009 Feb; 87 (2):392-8; discussion 398-9 PMID: 19161745 PMCID: 2930775 DOI: 10.1016/j.athoracsur.2008.11.001

44. Schomas DA, Miller RC, Donohue JH, Gill S, Thurmes PJ, Haddock MG, Quevedo JF, Gunderson LL. Intraperitoneal treatment for peritoneal mucinous carcinomatosis of appendiceal origin after operative management: long-term follow-up of the Mayo Clinic experience. Ann Surg. 2009 Apr; 249(4):588-95. PMID: 19300231 DOI: 10.1097/SLA.0b013e31819ec7e3

45. Daniels TB, Pollock BE, Miller RC, Lucchinetti CF, Leavitt JA, Brown PD. Radiation-induced optic neuritis after pituitary adenoma radiosurgery in a patient with multiple sclerosis: case report. J Neurooncol. 2009 Jun; 93 (2):263-7 Epub 2008 Dec 20 PMID: 19099198 PMCID: 2724634 DOI: 10.1007/s11060-008-9766-3

46. Pica A, Miller R, Villa S, Kadish SP, Anacak Y, Abusaris H, Ozyigit G, Baumert BG, Zaucha R, Haller G, Weber DC. The results of surgery, with or without radiotherapy, for primary spinal myxopapillary ependymoma: a retrospective study from the rare cancer network. Int J Radiat Oncol Biol Phys. 2009 Jul 15; 74(4):1114-20. Epub 2009 Feb 26. PMID: 19250760 DOI: 10.1016/j.ijrobp.2008.09.034

47. Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, Fry WA, Darling G, Johnson DH, Green MR, Miller RC, Ley J, Sause WT, Cox JD. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009 Aug 1; 374(9687):379-86. Epub 2009 Jul 24. PMID: 19632716 PMCID: 4407808 DOI: 10.1016/S0140-6736(09)60737-6

48. Gold DG, Miller RC, Haddock MG, Gunderson LL, Quevedo F, Donohue JH, Bhatia S, Nagorney DM. Adjuvant therapy for gallbladder carcinoma: the Mayo Clinic Experience. Int J Radiat Oncol Biol Phys. 2009 Sep 1; 75(1):150-5. Epub 2009 Mar 16. PMID: 19297105 DOI: 10.1016/j.ijrobp.2008.10.052

49. Miller RC, Iott MJ, Corsini MM. Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium. Int J Radiat Oncol Biol Phys. 2009 Oct 1; 75(2):364-8. PMID: 19735864 DOI: 10.1016/j.ijrobp.2008.11.069

50. Devisetty K, Mell LK, Salama JK, Schomas DA, Miller RC, Jani AB, Roeske JC, Aydogan B, Chmura SJ. A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy. Radiother Oncol. 2009 Nov; 93(2):298-301. Epub 2009 Aug 28. PMID: 19717198 DOI: 10.1016/j.radonc.2009.07.006

51. Macdonald OK, Kruse JJ, Miller JM, Garces YI, Brown PD, Miller RC, Foote RL. Proton beam radiotherapy versus three-dimensional conformal stereotactic body radiotherapy in primary


peripheral, early-stage non-small-cell lung carcinoma: a comparative dosimetric analysis. Int J Radiat Oncol Biol Phys. 2009 Nov 1; 75 (3):950-8 PMID: 19801106 DOI: 10.1016/j.ijrobp.2009.04.023

52. Neben-Wittich MA, Stauder MC, Quevedo F, Corsini MM, Iott MJ, Miller RC. Adjuvant radiotherapy and chemotherapy for resected pancreatic adenocarcinoma: Review of current evidence. European Journal of Clinical and Medical Oncology. 2010; 2(1). PMID: 0

53. Hallemeier CL, Kohli M, Chandan VS, Miller RC, Choo R. Multiple urinary bladder masses from metastatic prostate adenocarcinoma. Rare Tumors. 2010; 2(4):e65. Epub 2010 Dec 31. PMID: 21234257 PMCID: 3019600 DOI: 10.4081/rt.2010.e65

54. Miller RC. Problems in rare tumor study: A call for papers. Rare Tumors. 2010; 2(2):46-7. PMID: 0

55. Igdem S, Spiegel DY, Efstathiou J, Miller RC, Poortmans PM, Koca S, Kilic-Unsal D, Okkan S, Zietman A. Prostatic duct adenocarcinoma: clinical characteristics, treatment options, and outcomes - a Rare Cancer Network study. Onkologie. 2010; 33(4):169-73. Epub 2010 Mar 19. PMID: 20389142 DOI: 10.1159/000288710

56. Zhou Y, Boardman LA, Miller RC. Genetic testing for young-onset colorectal cancer: case report and evidence-based clinical guidelines. Radiol Oncol. 2010 Mar; 44 (1):57-61 Epub 2010 Mar 18 PMID: 22933892 PMCID: 3423677 DOI: 10.2478/v10019-010-0005-0

57. Hsu CC, Herman JM, Corsini MM, Winter JM, Callister MD, Haddock MG, Cameron JL, Pawlik TM, Schulick RD, Wolfgang CL, Laheru DA, Farnell MB, Swartz MJ, Gunderson LL, Miller RC. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol. 2010 Apr; 17(4):981-90. Epub 2010 Jan 20. PMID: 20087786 PMCID: 2840672 DOI: 10.1245/s10434-009-0743-7

58. Nguyen TD, Azria D, Brochon D, Poortmans P, Miller RC, Scandolaro L, Majewski W, Krengli M, Abacioglu U, Moretti L, Villa S, Akyol F, Jovenin N. Curative external beam radiotherapy in patients over 80 years of age with localized prostate cancer: a retrospective rare cancer network study. Crit Rev Oncol Hematol. 2010 Apr; 74(1):66-71. Epub 2009 May 05. PMID: 19419885 DOI: 10.1016/j.critrevonc.2009.04.004

59. Bardia A, Greeno E, Miller R, Alberts S, Dozois E, Haddock M, Limburg P. Is a solitary inguinal lymph node metastasis from adenocarcinoma of the rectum really a metastasis? Colorectal Dis. 2010 Apr; 12(4):312-5. Epub 2009 Feb 25. PMID: 19250258 DOI: 10.1111/j.1463-1318.2009.01821.x

60. Buyyounouski MK, Price RA, Harris EE, Miller R, Tome W, Schefter T, Parsai EI, Konski AA, Wallner PE. Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. Int J Radiat Oncol Biol Phys. 2010 Apr; 76(5):1297-304. PMID: 20338473 DOI: 10.1016/j.ijrobp.2009.09.078

61. Schomas DA, Quevedo JF, Donahue JM, Nichols FC 3rd, Romero Y, Miller RC. The prognostic importance of pathologically involved celiac node metastases in node-positive patients with carcinoma of the distal esophagus or gastroesophageal junction: a surgical series from the Mayo Clinic. Dis Esophagus. 2010 Apr; 23: (3)232-9. PMID: 19515184 DOI: 10.1111/j.1442-2050.2009.00990.x

62. Travis LB, Beard C, Allan JM, Dahl AA, Feldman DR, Oldenburg J, Daugaard G, Kelly JL, Dolan ME, Hannigan R, Constine LS, Oeffinger KC, Okunieff P, Armstrong G, Wiljer D, Miller RC, Gietema JA, van Leeuwen, Williams JP, Nichols CR, Einhorn LH, Fossa SD. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst. 2010 Aug 4; 102(15):1114-30. Epub 2010 Jun 28. PMID: 20585105 PMCID: 2914759 DOI: 10.1093/jnci/djq216


63. Stauder MC, Miller RC. Stereotactic Body Radiation Therapy (SBRT) for Unresectable Pancreatic Carcinoma. Cancers (Basel). 2010 Aug 9; 2 (3):1565-75 Epub 2010 Aug 09 PMID: 24281173 PMCID: 3837322 DOI: 10.3390/cancers2031565

64. Buyyounouski MK, Balter P, Lewis B, D'Ambrosio DJ, Dilling TJ, Miller RC, Schefter T, Tome W, Harris EE, Price RA, Konski AA, Wallner PE. Stereotactic body radiotherapy for early-stage non-small-cell lung cancer: report of the ASTRO Emerging Technology Committee. Int J Radiat Oncol Biol Phys. 2010 Sep 1; 78(1):3-10. Epub 2010 Jul 17. PMID: 20643514 DOI: 10.1016/j.ijrobp.2010.04.010

65. Atalar B, Miller RC, Dincbas FO, Geismar JH, Micke O, Akyurek S, Ozyar E. Adult langerhans cell histiocytosis of bones : a rare cancer network study. Acta Orthop Belg. 2010 Oct; 76(5):663-8. PMID: 21138223

66. Miller RC, Atherton PJ, Kabat BF, Fredericksen MB, Geno DM, Deschamps C, Jatoi A, Sloan JA, Romero Y. Marital status and quality of life in patients with esophageal cancer or Barrett's esophagus: the mayo clinic esophageal adenocarcinoma and Barrett's esophagus registry study. Dig Dis Sci. 2010 Oct; 55 (10):2860-8 Epub 2010 Jan 22 PMID: 20094784 DOI: 10.1007/s10620-009-1100-1

67. Mansfield A, Tafur A, Smithedajkul P, Corsini M, Quevedo F, Miller R. Mayo Clinic experience with very rare exocrine pancreatic neoplasms. Pancreas. 2010 Oct; 39(7):972-5. PMID: 20622706 DOI: 10.1097/MPA.0b013e3181df273b

68. Lott M, Neben-Wittich M, Quevedo JF, Miller RC. Adjuvant chemoradiotherapy for resected pancreas cancer. World J Gastrointest Surg. 2010 Nov 27; 2 (11):373-80 PMID: 21160900 PMCID: 3000450 DOI: 10.4240/wjgs.v2.i11.373

69. Haddock MG, Miller RC, Nelson H, Pemberton JH, Dozois EJ, Alberts SR, Gunderson LL. Combined modality therapy including intraoperative electron irradiation for locally recurrent colorectal cancer. Int J Radiat Oncol Biol Phys. 2011 Jan 1; 79(1):143-50. Epub 2010 Apr 13. PMID: 20395067 DOI: 10.1016/j.ijrobp.2009.10.046

70. Narang AK, Miller RC, Hsu CC, Bhatia S, Pawlik TM, Laheru D, Hruban RH, Zhou J, Winter JM, Haddock MG, Donohue JH, Schulick RD, Wolfgang CL, Cameron JL, Herman JM. Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Radiat Oncol. 2011; 6:126. Epub 2011 Sep 28. PMID: 21951377 PMCID: 3204241 DOI: 10.1186/1748-717X-6-126

71. Onal C, Li YX, Miller RC, Poortmans P, Constantinou N, Weber DC, Atasoy BM, Igdem S, Ozsahin M, Ozyar E. Treatment results and prognostic factors in primary thyroid lymphoma patients: a rare cancer network study. Ann Oncol. 2011 Jan; 22(1):156-64. Epub 2010 Jun 29. PMID: 20587509 DOI: 10.1093/annonc/mdq310

72. Winter JM, Narang AK, Mansfield AS, Herman JM, Cameron JL, Laheru D, Eckhauser FE, Olson MT, Hruban RH, Miller RC, Andersen DK. Resectable pancreatic small cell carcinoma. Rare Tumors. 2011 Mar 30; 3 (1):e5 PMID: 21464878 PMCID: 3070453 DOI: 10.4081/rt.2011.e5

73. Miller RC, Schwartz DJ, Sloan JA, Griffin PC, Deming RL, Anders JC, Stoffel TJ, Haselow RE, Schaefer PL, Bearden JD 3rd, Atherton PJ, Loprinzi CL, Martenson JA. Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4. Int J Radiat Oncol Biol Phys. 2011 Apr 1; 79 (5):1460-6 Epub 2010 Aug 26 PMID: 20800381 PMCID: 2995007 DOI: 10.1016/j.ijrobp.2010.01.031

74. Stauder MC, Macdonald OK, Olivier KR, Call JA, Lafata K, Mayo CS, Miller RC, Brown PD, Bauer HJ, Garces YI. Early pulmonary toxicity following lung stereotactic body radiation therapy delivered in consecutive daily fractions. Radiother Oncol. 2011 May; 99 (2):166-71 Epub 2011 May 14 PMID: 21571384 DOI: 10.1016/j.radonc.2011.04.002


75. Vos B, Rozema T, Miller RC, Hendlisz A, Van Laethem, Khanfir K, Weber DC, El Nakadi, Van Houtte. Small cell carcinoma of the esophagus: a multicentre Rare Cancer Network study. Dis Esophagus. 2011 May; 24(4):258-64. Epub 2010 Nov 12. PMID: 21073624 DOI: 10.1111/j.1442-2050.2010.01133.x

76. Smith RS, Miller RC. Incidence of brain metastasis in patients with esophageal carcinoma. World J Gastroenterol. 2011 May 21; 17(19):2407-10. PMID: 21633640 PMCID: 3103793 DOI: 10.3748/wjg.v17.i19.2407

77. Elkin EB, Klem ML, Gonzales AM, Ishill NM, Hodgson D, Ng AK, Marks LB, Weidhaas J, Freedman GM, Miller RC, Constine LS, Myrehaug S, Yahalom J. Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin's lymphoma: a multi-institutional, matched cohort study. J Clin Oncol. 2011 Jun 20; 29(18):2466-73. Epub 2011 May 16. PMID: 21576642 PMCID: 3138631 DOI: 10.1200/JCO.2010.32.4079

78. Neben-Wittich MA, Atherton PJ, Schwartz DJ, Sloan JA, Griffin PC, Deming RL, Anders JC, Loprinzi CL, Burger KN, Martenson JA, Miller RC. Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a Phase III trial of mometasone cream versus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4). Int J Radiat Oncol Biol Phys. 2011 Oct 1; 81 (2):397-402 Epub 2010 Oct 01 PMID: 20888137 PMCID: 3365545 DOI: 10.1016/j.ijrobp.2010.05.065

79. Call JA, Haddock MG, Quevedo JF, Larson DW, Miller RC. Intensity-modulated radiotherapy for squamous cell carcinoma of the anal canal: efficacy of a low daily dose to clinically negative regions. Radiat Oncol. 2011 Oct 6; 6:134 Epub 2011 Oct 06 PMID: 21978568 PMCID: 3198694 DOI: 10.1186/1748-717X-6-134

80. Bhatia S, Miszczyk L, Roelandts M, Nguyen TD, Boterberg T, Poortmans P, Vallow L, Dincbas FO, Lassen-Ramshad Y, Botros M, Miller RC. Radiotherapy for marginally resected, unresectable or recurrent giant cell tumor of the bone: a rare cancer network study. Rare Tumors. 2011 Oct 21; 3 (4):e48 Epub 2011 Dec 16 PMID: 22355503 PMCID: 3282453 DOI: 10.4081/rt.2011.e48

81. Hallemeier CL, Botros M, Corsini MM, Haddock MG, Gunderson LL, Miller RC. Preoperative CA 19-9 level is an important prognostic factor in patients with pancreatic adenocarcinoma treated with surgical resection and adjuvant concurrent chemoradiotherapy. Am J Clin Oncol. 2011 Dec; 34(6):567-72. PMID: 21150564 DOI: 10.1097/COC.0b013e3181f946fc

82. Thariat J, Kirova Y, Sio T, Choussy O, Vees H, Schick U, Poissonnet G, Saada E, Thyss A, Miller RC. Mucosal Kaposi sarcoma, a rare cancer network study. Rare Tumors. 2012; 4(4):156-61.

83. Anacak Y, Miller RC, Constantinou N, Mamusa AM, Epelbaum R, Li Y, Calduch AL, Kowalczyk A, Weber DC, Kadish SP, Bese N, Poortmans P, Kamer S, Ozsahin M. Primary mucosa-associated lymphoid tissue lymphoma of the salivary glands: a multicenter Rare Cancer Network study. Int J Radiat Oncol Biol Phys. 2012 Jan 1; 82(1):315-20. Epub 2010 Nov 13. PMID: 21075560 DOI: 10.1016/j.ijrobp.2010.09.046

84. Patel AB, Hallemeier CL, Petersen IA, Jensen AW, Osborn TG, Miller RC. Acute and late toxicities of radiotherapy for patients with discoid lupus erythematosus: a retrospective case-control study. Radiat Oncol. 2012 Feb 16; 7:22 PMID: 22340665 PMCID: 3296611 DOI: 10.1186/1748-717X-7-22

85. Botros M, Chang K, Miller R, Krishnan S, Iott M. Recurrent invasive lobular carcinoma presenting as a ruptured breast implant. Radiol Oncol. 2012 Mar; 46(1):23-7. Epub 2011 Oct 08. PMID: 22933976 PMCID: 3423769 DOI: 10.2478/v10019-011-0032-5

86. Khanfir K, Kallel A, Villette S, Belkacemi Y, Vautravers C, Nguyen T, Miller R, Li YX, Taghian AG, Boersma L, Poortmans P, Goldberg H, Vees H, Senkus E, Igdem S, Ozsahin M, Jeanneret Sozzi. Management of adenoid cystic carcinoma of the breast: a Rare Cancer Network study. Int J


Radiat Oncol Biol Phys. 2012 Apr 1; 82(5):2118-24. Epub 2011 May 11. PMID: 21570212 DOI: 10.1016/j.ijrobp.2010.12.008

87. Ahmed KA, Stauder MC, Miller RC, Bauer HJ, Rose PS, Olivier KR, Brown PD, Brinkmann DH, Laack NN. Stereotactic body radiation therapy in spinal metastases. Int J Radiat Oncol Biol Phys. 2012 Apr 1; 82 (5):e803-9 Epub 2012 Feb 11 PMID: 22330988 DOI: 10.1016/j.ijrobp.2011.11.036

88. Barney BM, Olivier KR, Miller RC, Haddock MG. Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma. Radiat Oncol. 2012 May 3; 7:67 Epub 2012 May 03 PMID: 22553982 PMCID: 3464963 DOI: 10.1186/1748-717X-7-67

89. Thariat J, Julieron M, Brouchet A, Italiano A, Schouman T, Marcy PY, Odin G, Lacout A, Dassonville O, Peyrottes-Birstwisles I, Miller R, Thyss A, Isambert N. Osteosarcomas of the mandible: are they different from other tumor sites? Crit Rev Oncol Hematol. 2012 Jun; 82(3):280-95. Epub 2011 Aug 24. PMID: 21868246 DOI: 10.1016/j.critrevonc.2011.07.001

90. Patel A, Ozsahin M, Mirimanoff RO, Bhatia S, Chang K, Miller RC. The Rare Cancer Network: achievements from 1993 to 2012. Rare Tumors. 2012 Jun 26; 4 (3):e35 Epub 2012 Sept 27 PMID: 23087791 PMCID: 3475942 DOI: 10.4081/rt.2012.e35

91. Atherton PJ, Burger KN, Loprinzi CL, Neben Wittich MA, Miller RC, Jatoi A, Sloan JA. Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993). Support Care Cancer. 2012 Aug; 20 (8):1729-35 Epub 2011 Sept 16 PMID: 21922203 PMCID: 3391325 DOI: 10.1007/s00520-011-1266-x

92. Foote RL, Stafford SL, Petersen IA, Pulido JS, Clarke MJ, Schild SE, Garces YI, Olivier KR, Miller RC, Haddock MG, Yan E, Laack NN, Arndt CA, Buskirk SJ, Miller VL, Brent CR, Kruse JJ, Ezzell GA, Herman MG, Gunderson LL, Erlichman C, Diasio RB. The clinical case for proton beam therapy. Radiat Oncol. 2012 Oct 22; 7:174 PMID: 23083010 PMCID: 3549771 DOI: 10.1186/1748-717X-7-174

93. Villa S, Miller RC, Krengli M, Abusaris H, Baumert BG, Servagi-Vernat S, Igdem S, Lucas A, Boluda S, Mirimanoff RO. Primary pineal tumors: outcome and prognostic factors--a study from the Rare Cancer Network (RCN). Clin Transl Oncol. 2012 Nov; 14(11):827-34. Epub 2012 Aug 23. PMID: 22914906 DOI: 10.1007/s12094-012-0869-0

94. Barney BM, Olivier KR, Macdonald OK, Fong de Los Santos LE, Miller RC, Haddock MG. Clinical outcomes and dosimetric considerations using stereotactic body radiotherapy for abdominopelvic tumors. Am J Clin Oncol. 2012 Dec; 35 (6):537-42 PMID: 21659830 DOI: 10.1097/COC.0b013e31821f876a

95. Mayo CS, Zankowski C, Herman M, Miller R, Olivier K, Vincent A, Suominen J. A method to vectorize the dose distribution, the dose volume histogram and create a dose vector histogram. Med Phys. 2013 Jan; 40: (1)011717. PMID: 23298087 DOI: 10.1118/1.4769111

96. Call JA, Haddock MG, Quevedo JF, Larson DW, Miller RC. Concurrent chemotherapy and intensity modulated radiation therapy in the treatment of anal cancer: A retrospective review from a large academic center. Pract Radiat Oncol. 2013 Jan-Mar; 3 (1):26-31 Epub 2012 Apr 03 PMID: 24674260 DOI: 10.1016/j.prro.2012.02.005

97. Abu Dayyeh BK, Vandamme JJ, Miller RC, Baron TH. Esophageal self-expandable stent material and mesh grid density are the major determining factors of external beam radiation dose perturbation: results from a phantom model. Endoscopy. 2013; 45: (1)42-7. PMID: 23254405 DOI: 10.1055/s-0032-1325960

98. Hallemeier CL, Stauder MC, Miller RC, Garces YI, Foote RL, Sarkaria JN, Bauer HJ, Mayo CS, Olivier KR. Lung stereotactic body radiotherapy using a coplanar versus a non-coplanar beam


technique: a comparison of clinical outcomes. J Radiosurg SBRT. 2013; 2 (3):225-233 PMID: 29296365 PMCID: 5658814

99. Stauder MC, Romero Y, Kabat B, Atherton PJ, Geno D, Deschamps C, Jatoi A, Sloan JA, Botros M, Jung KW, Arora AS, Miller RC, EABE Registry Consortium. Overall survival and self-reported fatigue in patients with esophageal cancer. Support Care Cancer. 2013 Feb; 21 (2):511-9 Epub 2012 July 29 PMID: 22842921 DOI: 10.1007/s00520-012-1537-1

100. Thariat J, Schouman T, Brouchet A, Sarini J, Miller RC, Reychler H, Ray-Coquard I, Italiano A, Verite C, Sohawon S, Bompas E, Dassonville O, Salas S, Aldabbagh K, Maingon P, de La MotteRouge T, Kurtz JE, Usseglio J, Kerbrat P, Raoul G, Lotz JP, Bar-Sela G, Brugieres L, Chaigneau L, Saada E, Odin G, Marcy PY, Thyss A, Julieron M. Osteosarcomas of the mandible: multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, Rare Cancer Network, GETTEC/REFCOR and SFCE. Ann Oncol. 2013 Mar; 24(3):824-31. Epub 2012 Nov 06. PMID: 23131392 DOI: 10.1093/annonc/mds507

101. Atherton PJ, Halyard MY, Sloan JA, Miller RC, Deming RL, Tai TH, Stien KJ, Martenson JA Jr. Assessment of patient-reported measures of bowel function before and after pelvic radiotherapy: an ancillary study of the North Central Cancer Treatment Group study N00CA. Support Care Cancer. 2013 Apr; 21 (4):1193-9 Epub 2012 Nov 15 PMID: 23151649 PMCID: 4018822 DOI: 10.1007/s00520-012-1648-8

102. Miller RC, Lodge M, Murad MH, Jones B. Controversies in clinical trials in proton radiotherapy: the present and the future. Semin Radiat Oncol. 2013 Apr; 23(2):127-33. PMID: 23473690 DOI: 10.1016/j.semradonc.2012.11.004

103. Hallemeier CL, Iott MJ, Martenson JA, Haddock MG, Zhao XC, Miller RC. A pilot study examining circulating interleukin-6 and transforming growth factor-beta levels during pelvic radiation therapy. Am J Clin Oncol. 2013 Aug; 36(4):344-7. PMID: 22772427 DOI: 10.1097/COC.0b013e318248dc36

104. Barney BM, Markovic SN, Laack NN, Miller RC, Sarkaria JN, Macdonald OK, Bauer HJ, Olivier KR. Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT). Int J Radiat Oncol Biol Phys. 2013 Sep 1; 87 (1):73-80 PMID: 23920388 DOI: 10.1016/j.ijrobp.2013.05.012

105. Ahmed KA, Barney BM, Macdonald OK, Miller RC, Garces YI, Laack NN, Haddock MG, Foote RL, Olivier KR. Stereotactic body radiotherapy in the treatment of adrenal metastases. Am J Clin Oncol. 2013 Oct; 36(5):509-13. PMID: 22781389 DOI: 10.1097/COC.0b013e3182569189

106. Mayo C, Conners S, Warren C, Miller R, Court L, Popple R. Demonstration of a software design and statistical analysis methodology with application to patient outcomes data sets. Med Phys. 2013 Nov; 40 (11):111718 PMID: 24320426 PMCID: 3815052 DOI: 10.1118/1.4824917

107. Pohar S, Fung CY, Hopkins S, Miller R, Azawi S, Arnone A, Patton C, Olsen C. American Society for Radiation Oncology (ASTRO) 2012 Workforce Study: the radiation oncologists' and residents' perspectives. Int J Radiat Oncol Biol Phys. 2013 Dec 1; 87(5):1135-40. Epub 2013 Oct 22. PMID: 24161423 DOI: 10.1016/j.ijrobp.2013.08.038

108. Patel K, Stephens EK, Miller RC, Jatoi A. Incidence and outcomes of chemotherapy and radiation in morbidly obese patients with locally advanced lung and esophageal cancers: a single-institution experience. Cancer Control. 2014 Jan; 21 (1):63-6 PMID: 24357743 DOI: 10.1177/107327481402100109

109. Owen D, Olivier KR, Song L, Mayo CS, Miller RC, Nelson K, Bauer H, Brown PD, Park SS, Ma DJ, Garces YI. Safety and Tolerability of SBRT after High-Dose External Beam Radiation to the Lung. Front Oncol. 2014; 4:376 Epub 2015 Jan 14 PMID: 25642416 PMCID: 4294121 DOI: 10.3389/fonc.2014.00376


110. Sio TT, Mansfield AS, Grotz TE, Graham RP, Molina JR, Que FG, Miller RC. Concurrent MCL1 and JUN amplification in pseudomyxoma peritonei: a comprehensive genetic profiling and survival analysis. J Hum Genet. 2014 Mar; 59 (3):124-8 Epub 2013 Dec 26 PMID: 24369359 PMCID: 3973125 DOI: 10.1038/jhg.2013.132

111. Owen D, Laack NN, Mayo CS, Garces YI, Park SS, Bauer HJ, Nelson K, Miller RC, Brown PD, Olivier KR. Outcomes and toxicities of stereotactic body radiation therapy for non-spine bone oligometastases. Pract Radiat Oncol. 2014 Mar-Apr; 4 (2):e143-e149 Epub 2013 June 29 PMID: 24890360 PMCID: 4364394 DOI: 10.1016/j.prro.2013.05.006

112. Travis LB, Fossa SD, Sesso HD, Frisina RD, Herrmann DN, Beard CJ, Feldman DR, Pagliaro LC, Miller RC, Vaughn DJ, Einhorn LH, Cox NJ, Dolan ME, Platinum Study Group. Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J Natl Cancer Inst. 2014 Mar 12; 106 (5) PMID: 24623533 PMCID: 4568989 DOI: 10.1093/jnci/dju044

113. Hallemeier CL, You YN, Larson DW, Dozois EJ, Nelson H, Klein KA, Miller RC, Haddock MG. Multimodality therapy including salvage surgical resection and intraoperative radiotherapy for patients with squamous-cell carcinoma of the anus with residual or recurrent disease after primary chemoradiotherapy. Dis Colon Rectum. 2014 Apr; 57: (4)442-8. PMID: 24608300 DOI: 10.1097/DCR.0000000000000071

114. Leenstra JL, Miller RC, Qin R, Martenson JA, Dornfeld KJ, Bearden JD, Puri DR, Stella PJ, Mazurczak MA, Klish MD, Novotny PJ, Foote RL, Loprinzi CL. Doxepin rinse versus placebo in the treatment of acute oral mucositis pain in patients receiving head and neck radiotherapy with or without chemotherapy: a phase III, randomized, double-blind trial (NCCTG-N09C6 [Alliance]). J Clin Oncol. 2014 May 20; 32 (15):1571-7 Epub 2014 Apr 14 PMID: 24733799 PMCID: 4026580 DOI: 10.1200/JCO.2013.53.2630

115. Mirimanoff RO, Ozsahin M, Thariat J, Ozyar E, Schick U, Pehlivan B, Krengli M, Pellanda AF, Vees H, Cai L, Scandolaro L, Belkacemi Y, Villa S, Igdem S, Lutsyk M, Miller RC. History of the rare cancer network and past research. Rare Tumors. 2014 Jul 30; 6 (3):5462 Epub 2014 Aug 06 PMID: 25276325 PMCID: 4178278 DOI: 10.4081/rt.2014.5462

116. Ozsahin M, Mirimanoff RO, Thariat J, Sun XS, Atalar B, Lassen-Ramshad Y, Ugurluer G, Krishnan S, Hallemeier C, Houtte PV, Krengli M, Zhang LJ, Chang K, Funk R, Rooney J, Miller RC. The rare cancer network: ongoing studies and future strategy. Rare Tumors. 2014 Jul 30; 6 (3):5465 Epub 2014 Aug 08 PMID: 25276326 PMCID: 4178279 DOI: 10.4081/rt.2014.5465

117. Sheehan M, Timlin C, Peach K, Binik A, Puthenparampil W, Lodge M, Kehoe S, Brada M, Burnet N, Clarke S, Crellin A, Dunn M, Fossati P, Harris S, Hocken M, Hope T, Ives J, Kamada T, London AJ, Miller R, Parker M, Pijls-Johannesma M, Savulescu J, Short S, Skene L, Tsujii H, Tuan J, Weijer C. Position statement on ethics, equipoise and research on charged particle radiation therapy. J Med Ethics. 2014 Aug; 40(8):572-5. Epub 2013 Sep 17. PMID: 24045770 DOI: 10.1136/medethics-2012-101290

118. Sio TT, Jensen AR, Miller RC, Fong de los Santos LE, Hallemeier CL, Foster NR, Park SS, Bauer HJ, Chang K, Garces YI, Olivier KR. Influence of patient's physiologic factors and immobilization choice with stereotactic body radiotherapy for upper lung tumors. J Appl Clin Med Phys. 2014 Sep 8; 15 (5):4931 Epub 2014 Sept 08 PMID: 25207580 PMCID: 5711083 DOI: 10.1120/jacmp.v15i5.4931

119. Morganti AG, Falconi M, van Stiphout RG, Mattiucci GC, Alfieri S, Calvo FA, Dubois JB, Fastner G, Herman JM, Maidment BW 3rd, Miller RC, Regine WF, Reni M, Sharma NK, Ippolito E, Valentini V. Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer. Int J Radiat Oncol Biol Phys. 2014 Nov 15; 90(4):911-7. Epub 2014 Sep 11. PMID: 25220717 DOI: 10.1016/j.ijrobp.2014.07.024


120. Liang JJ, Sio TT, Slusser JP, Lennon RJ, Miller RC, Sandhu G, Prasad A. Outcomes after percutaneous coronary intervention with stents in patients treated with thoracic external beam radiation for cancer. JACC Cardiovasc Interv. 2014 Dec; 7(12):1412-20. Epub 2014 Nov 12. PMID: 25459527 DOI: 10.1016/j.jcin.2014.05.035

121. Kottschade LA, Grotz TE, Dronca RS, Salomao DR, Pulido JS, Wasif N, Jakub JW, Bagaria SP, Kumar R, Kaur JS, Morita SY, Moran SL, Nguyen JT, Nguyen EC, Hand JL, Erickson LA, Brewer JD, Baum CL, Miller RC, Swanson DL, Lowe V, Markovic SN. Rare presentations of primary melanoma and special populations: a systematic review. Am J Clin Oncol. 2014 Dec; 37 (6):635-41 PMID: 23563206 PMCID: 4349521 DOI: 10.1097/COC.0b013e3182868e82

122. Timlin C, Warren DR, Rowland B, Madkhali A, Loken J, Partridge M, Jones B, Kruse J, Miller R. 3D calculation of radiation-induced second cancer risk including dose and tissue response heterogeneities. Med Phys. 2015 Feb; 42: (2)866-76. PMID: 25652499 DOI: 10.1118/1.4905158

123. Jayakrishnan R, Chang K, Ugurluer G, Miller RC, Sio TT. Doxepin for Radiation Therapy-Induced Mucositis Pain in the Treatment of Oral Cancers. Oncol Rev. 2015 Feb 10; 9 (1):290 Epub 2015 Dec 09 PMID: 26779314 PMCID: 4698596 DOI: 10.4081/oncol.2015.290

124. Owen D, Olivier KR, Mayo CS, Miller RC, Nelson K, Bauer H, Brown PD, Park SS, Ma DJ, Garces YI. Outcomes of stereotactic body radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules. Radiat Oncol. 2015 Feb 18; 10:43 PMID: 25889747 PMCID: 4341868 DOI: 10.1186/s13014-015-0340-9

125. Lehmann HI, Richter D, Prokesch H, Graeff C, Prall M, Simoniello P, Fournier C, Bauer J, Kaderka R, Weymann A, Szabo G, Sonnenberg K, Constantinescu AM, Johnson SB, Misiri J, Takami M, Miller RC, Herman MG, Asirvatham SJ, Brons S, Jakel O, Haberer T, Debus J, Durante M, Bert C, Packer DL. Atrioventricular node ablation in Langendorff-perfused porcine hearts using carbon ion particle therapy: methods and an in vivo feasibility investigation for catheter-free ablation of cardiac arrhythmias. Circ Arrhythm Electrophysiol. 2015 Apr; 8: (2)429-38. PMID: 25609687 DOI: 10.1161/CIRCEP.114.002436

126. Weber DC, Wang Y, Miller R, Villa S, Zaucha R, Pica A, Poortmans P, Anacak Y, Ozygit G, Baumert B, Haller G, Preusser M, Li J. Long-term outcome of patients with spinal myxopapillary ependymoma: treatment results from the MD Anderson Cancer Center and institutions from the Rare Cancer Network. Neuro Oncol. 2015 Apr; 17 (4):588-95 Epub 2014 Oct 09 PMID: 25301811 PMCID: 4483075 DOI: 10.1093/neuonc/nou293

127. Mattiucci GC, Falconi M, VAN Stiphout RG, Alfieri S, Calvo FA, Herman JM, Maidment BW 3rd, Miller RC, Regine WF, Reni M, Sharma N, Partelli S, Genovesi D, Balducci M, Deodato F, Valentini V, Morganti AG. Adjuvant Chemoradiation in Pancreatic Cancer: A Pooled Analysis in Elderly (>/=75 years) Patients. Anticancer Res. 2015 Jun; 35(6):3441-6. PMID: 26026108

128. Birckhead BJ, Peterson JL, Patel AB, Miller RC. Palliative Radiation for Leukemic Arthropathy from Human T-Cell Lymphoma Virus-associated Adult T-Cell Leukemia Lymphoma. Rare Tumors. 2015 Sep 7; 7 (3):5834 Epub 2015 Sept 07 PMID: 26500728 PMCID: 4600990 DOI: 10.4081/rt.2015.5834

129. Wang J, Narang AK, Sugar EA, Luber B, Rosati LM, Hsu CC, Fuller CD, Pawlik TM, Miller RC, Czito BG, Tuli R, Crane CH, Ben-Josef E, Thomas CR Jr, Herman JM. Evaluation of Adjuvant Radiation Therapy for Resected Gallbladder Carcinoma: A Multi-institutional Experience. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S1100-6. PMID: 26224402 DOI: 10.1245/s10434-015-4685-y

130. Anand A, Bues M, Rule WG, Keole SR, Beltran CJ, Yin J, Haddock MG, Hallemeier CL, Miller RC, Ashman JB. Scanning proton beam therapy reduces normal tissue exposure in pelvic radiotherapy for anal cancer. Radiother Oncol. 2015 Dec; 117 (3):505-8 Epub 2015 Nov 17 PMID: 26597231 DOI: 10.1016/j.radonc.2015.10.027


131. Brett CL, Miller DH, Jiang L, Wolfsen HC, Attia S, Hintenlang L, Jagadesh N, Miller RC. Dedifferentiated liposarcoma of the esophagus: A case report and selected review of the literature Rare Tumors. 2016; 8: (4)201-2.

132. Kaleem TA, Schild MH, Miller D, Jha A, Cortese C, Attia S, Miller RC. Langerhanâ€™s cell sarcoma: Two case reports Rare Tumors. 2016; 8: (1)17-9.

133. Sio TT, Vu CC, Sohawon S, Van Houtte P, Thariat J, Novotny PJ, Miller RC, Bar-Sela G. Extraskeletal Osteosarcoma: An International Rare Cancer Network Study. Am J Clin Oncol. 2016 Feb; 39 (1):32-6 PMID: 24401667 PMCID: 4892767 DOI: 10.1097/COC.0000000000000005

134. Call JA, Prendergast BM, Jensen LG, Ord CB, Goodman KA, Jacob R, Mell LK, Thomas CR Jr, Jabbour SK, Miller RC. Intensity-modulated Radiation Therapy for Anal Cancer: Results From a Multi-Institutional Retrospective Cohort Study. Am J Clin Oncol. 2016 Feb; 39: (1)8-12. PMID: 24401669 DOI: 10.1097/COC.0000000000000009

135. Sio TT, Merrell KW, Beltran CJ, Ashman JB, Hoeft KA, Miller RC, Whitaker TJ, Wurgler SK, Tryggestad EJ. Spot-scanned pancreatic stereotactic body proton therapy: A dosimetric feasibility and robustness study. Phys Med. 2016 Feb; 32: (2)331-42. PMID: 26883369 DOI: 10.1016/j.ejmp.2015.12.009

136. Merrell KW, Haddock MG, Quevedo JF, Harmsen WS, Kendrick ML, Miller RC, Hallemeier CL. Predictors of Locoregional Failure and Impact on Overall Survival in Patients With Resected Exocrine Pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2016 Mar 1; 94: (3)561-70. PMID: 26867884 DOI: 10.1016/j.ijrobp.2015.11.003

137. Kaleem TA, Schild MH, Miller D, Jha A, Cortese C, Attia S, Miller RC. Langerhan's Cell Sarcoma: Two Case Reports. Rare Tumors. 2016 Mar 21; 8 (1):6140 Epub 2016 Apr 06 PMID: 27134713 PMCID: 4827650 DOI: 10.4081/rt.2016.6140

138. Ugurluer G, Chang K, Gamez ME, Arnett AL, Jayakrishnan R, Miller RC, Sio TT. Genome-based Mutational Analysis by Next Generation Sequencing in Patients with Malignant Pleural and Peritoneal Mesothelioma. Anticancer Res. 2016 May; 36: (5)2331-8. PMID: 27127140

139. Sio TT, Martenson JA Jr, Haddock MG, Novotny PJ, Gores GJ, Alberts SR, Miller RC, Heimbach JK, Rosen CB. Outcome of Transplant-fallout Patients With Unresectable Cholangiocarcinoma. Am J Clin Oncol. 2016 Jun; 39 (3):271-5 PMID: 24921218 PMCID: 4309741 DOI: 10.1097/COC.0000000000000056

140. Habboush J, Hollant L, Smart B, Single M, Gaines K, Patel A, Miller R. Characteristics and Patterns of Rare Malignancies Published in Rare Tumors. Rare Tumors. 2016 Jun 28; 8 (2):6148 Epub 2016 June 28 PMID: 27441071 PMCID: 4935820 DOI: 10.4081/rt.2016.6148

141. Mayo CS, Pisansky TM, Petersen IA, Yan ES, Davis BJ, Stafford SL, Garces YI, Miller RC, Martenson JA, Mutter RW, Choo R, Hallemeier CL, Laack NN, Ma DJ, Olivier KR, Keole SR, Fatyga M, Foote RL, Haddock MG. Establishment of practice standards in nomenclature and prescription to enable construction of software and databases for knowledge-based practice review. Pract Radiat Oncol. 2016 Jul-Aug; 6: (4)e117-26. PMID: 26825250 DOI: 10.1016/j.prro.2015.11.001

142. Miller RC, Petereit DG, Sloan JA, Liu H, Martenson JA, Bearden JD 3rd, Sapiente R, Seeger GR, Mowat RB, Liem B, Iott MJ, Loprinzi CL, Alliance for Clinical Trials in Oncology. N08C9 (Alliance): A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 Jul 15; 95 (4):1168-74 Epub 2016 Apr 23 PMID: 27354129 PMCID: 4955745 DOI: 10.1016/j.ijrobp.2016.01.063

143. Sio TT, Atherton PJ, Birckhead BJ, Schwartz DJ, Sloan JA, Seisler DK, Martenson JA, Loprinzi CL, Griffin PC, Morton RF, Anders JC, Stoffel TJ, Haselow RE, Mowat RB, Wittich MA, Bearden JD


3rd, Miller RC. Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer. 2016 Sep; 24 (9):3847-55 Epub 2016 Apr 14 PMID: 27075674 PMCID: 4967382 DOI: 10.1007/s00520-016-3213-3

144. Ugurluer G, Miller RC, Li Y, Thariat J, Ghadjar P, Schick U, Ozsahin M. Primary Hepatic Lymphoma: A Retrospective, Multicenter Rare Cancer Network Study. Rare Tumors. 2016 Sep 5; 8 (3):6502 Epub 2016 Oct 06 PMID: 27746888 PMCID: 5064304 DOI: 10.4081/rt.2016.6502

145. Sio TT, Wilson ZC, Stauder MC, Bhatia S, Martenson JA, Quevedo JF, Schomas DA, Miller RC. Long-term Treatment Outcomes for Locally Advanced Esophageal Cancer: A Single-Institution Experience. Am J Clin Oncol. 2016 Oct; 39 (5):448-52 PMID: 24879469 DOI: 10.1097/COC.0000000000000089

146. Sio TT, Liang JJ, Chang K, Novotny PJ, Prasad A, Miller RC. Outcomes After Curative Thoracic Radiotherapy in Patients With Coronary Artery Disease and Existing Cardiac Stents. Am J Clin Oncol. 2016 Dec; 39 (6):549-555 PMID: 24879471 DOI: 10.1097/COC.0000000000000092

147. Sio TT, Liang JJ, Chang K, Jayakrishnan R, Novotny PJ, Prasad A, Miller RC. Dosimetric Correlate of Cardiac-Specific Survival Among Patients Undergoing Coronary Artery Stenting After Thoracic Radiotherapy for Cancer. Am J Clin Oncol. 2017 Apr; 40: (2)133-139. PMID: 25268066 DOI: 10.1097/COC.0000000000000135

148. Lehmann HI, Deisher AJ, Takami M, Kruse JJ, Song L, Anderson SE, Cusma JT, Parker KD, Johnson SB, Asirvatham SJ, Miller RC, Herman MG, Packer DL. External Arrhythmia Ablation Using Photon Beams: Ablation of the Atrioventricular Junction in an Intact Animal Model. Circ Arrhythm Electrophysiol. 2017 Apr; 10: (4). PMID: 28408649 DOI: 10.1161/CIRCEP.116.004304

149. Habboush Y, Shannon RP, Niazi SK, Hollant L, Single M, Gaines K, Smart B, Chimato NT, Heckman MG, Buskirk SJ, Vallow LA, Tzou KS, Ko SJ, Peterson JL, Biers HA, Day AB, Nelson KA, Sloan JA, Halyard MY, Miller RC. Patient-reported distress and survival among patients receiving definitive radiation therapy. Adv Radiat Oncol. 2017 Apr-Jun; 2 (2):211-219 Epub 2017 Mar 20 PMID: 28740934 PMCID: 5514245 DOI: 10.1016/j.adro.2017.03.004

150. Fender EA, Liang JJ, Sio TT, Stulak JM, Lennon RJ, Slusser JP, Ashman JB, Miller RC, Herrmann J, Prasad A, Sandhu GS. Percutaneous revascularization in patients treated with thoracic radiation for cancer. Am Heart J. 2017 May; 187:98-103. PMID: 28454813 DOI: 10.1016/j.ahj.2017.02.014

151. Jagadesh N, Miller DH, Schenk W, Attia S, Sherman CE, Cortese C, May BC, Miller RC. Recurrent myxoinflammatory fibroblastic sarcoma: a case report. Clin Case Rep. 2017 Jun; 5 (6):871-875 Epub 2017 Apr 20 PMID: 28588829 PMCID: 5458025 DOI: 10.1002/ccr3.949

152. Miller RC, Goyal S, McClelland S 3rd, Motwani S, Mayo C, Kaleem T, Videtic G, Hintenlang K. ASTRO's Advances in Radiation Oncology: Success to date and future plans. Adv Radiat Oncol. 2017 Jul-Sep; 2 (3):245-248 Epub 2017 May 26 PMID: 29114588 PMCID: 5605320 DOI: 10.1016/j.adro.2017.05.004

153. Thariat J, Sio T, Blanchard P, Patel S, Demizu Y, Ampil F, Guihard S, Miller RC, Karlsson U, Krengli M, Giap H, Nguyen N. Using Proton Beam Therapy in the Elderly Population: A Snapshot of Current Perception and Practice. Int J Radiat Oncol Biol Phys. 2017 Jul 15; 98 (4):840-842 Epub 2017 Jan 06 PMID: 28258888 DOI: 10.1016/j.ijrobp.2017.01.007

154. Patel AJ, Tzou KS, Heckman MG, Thomas CS, Lee RJ, Paryani N, Peterson JL, Miller RC, Ko SJ, Vallow LA, Buskirk SJ. Estimation of PSA Half-Life Following Salvage Radiation Therapy Journal of Cancer Therapy. 2017.

155. Patel AB, Tzou KS, Single M, Hollant L, Smart B, Gaines K, Sherman C, Peterson JL, Ko SJ, Vallow LA, Miller RC, Buskirk SJ. Radiation therapy prophylaxis for heterotopic ossification in non-hip sites. Journal of Cancer Therapy. 2017.


156. Waddle MR, Sio TT, Van Houten HK, Foote RL, Keole SR, Schild SE, Laack N, Daniels TB, Crown W, Shah ND, Miller RC. Photon and Proton Radiation Therapy Utilization in a Population of More Than 100 Million Commercially Insured Patients. Int J Radiat Oncol Biol Phys. 2017 Dec 1; 99 (5):1078-1082 Epub 2017 Aug 02 PMID: 28939229 DOI: 10.1016/j.ijrobp.2017.07.042

157. Fender EA, Chandrashekar P, Liang JJ, Dhar PR, Sio TT, Stulak JM, Lennon RJ, Slusser JP, Ashman JB, Miller RC, Herrmann J, Prasad A, Sandhu GS. Coronary artery bypass grafting in patients treated with thoracic radiation: a case-control study. Open Heart. 2018; 5 (1):e000766 Epub 2018 Feb 14 PMID: 29531769 PMCID: 5845399 DOI: 10.1136/openhrt-2017-000766

158. Hintenlang LL, Miller DH, Kaleem T, Patel N, May BC, Tzou KS, Vallow LA, Buskirk SJ, Miller RC, Ko SJ, Jaeckle KA, Trifiletti DM, Peterson JL. Treatment of a glioblastoma multiforme dural metastasis with stereotactic radiosurgery: A case report and select review of the literature. J Clin Neurosci. 2018 Feb; 48:118-121 Epub 2017 Nov 26 PMID: 29183682 DOI: 10.1016/j.jocn.2017.11.003

159. Whitaker TJ, Mayo CS, Ma DJ, Haddock MG, Miller RC, Corbin KS, Neben-Wittich M, Leenstra JL, Laack NN, Fatyga M, Schild SE, Vargas CE, Tzou KS, Hadley AR, Buskirk SJ, Foote RL. Data collection of patient outcomes: one institution's experience. J Radiat Res. 2018 Mar 1; 59 (suppl_1):i19-i24 PMID: 29538757 PMCID: 5868196 DOI: 10.1093/jrr/rry013

160. Hobbs CJ, Ko SJ, Paryani NN, Accurso JM, Olivier KR, Garces YI, Park SS, Hallemeier CL, Schild SE, Vora SA, Ashman JB, Rule WG, Bowers JR, Heckman MG, Diehl NN, Miller RC. Stereotactic Body Radiotherapy for Medically Inoperable Stage I-II Non-Small Cell Lung Cancer: The Mayo Clinic Experience. Mayo Clin Proc Innov Qual Outcomes. 2018 Mar; 2 (1):40-48 Epub 2017 Dec 26 PMID: 30225431 PMCID: 6124323 DOI: 10.1016/j.mayocpiqo.2017.11.001

161. Mayo CS, Moran JM, Bosch W, Xiao Y, McNutt T, Popple R, Michalski J, Feng M, Marks LB, Fuller CD, Yorke E, Palta J, Gabriel PE, Molineu A, Matuszak MM, Covington E, Masi K, Richardson SL, Ritter T, Morgas T, Flampouri S, Santanam L, Moore JA, Purdie TG, Miller RC, Hurkmans C, Adams J, Jackie Wu QR, Fox CJ, Siochi RA, Brown NL, Verbakel W, Archambault Y, Chmura SJ, Dekker AL, Eagle DG, Fitzgerald TJ, Hong T, Kapoor R, Lansing B, Jolly S, Napolitano ME, Percy J, Rose MS, Siddiqui S, Schadt C, Simon WE, Straube WL, St James ST, Ulin K, Yom SS, Yock TI. American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology. Int J Radiat Oncol Biol Phys. 2018 Mar 15; 100 (4):1057-1066 Epub 2017 Dec 15 PMID: 29485047 DOI: 10.1016/j.ijrobp.2017.12.013

162. Atalar B, Ozsahin M, Call J, Napieralska A, Kamer S, Villa S, Erpolat P, Negretti L, Lassen-Ramshad Y, Onal C, Akyurek S, Ugurluer G, Baumert BG, Servagi-Vernat S, Miller RC, Ozyar E, Sio TT. Treatment outcome and prognostic factors for adult patients with medulloblastoma: The Rare Cancer Network (RCN) experience. Radiother Oncol. 2018 Apr; 127 (1):96-102 Epub 2018 Jan 17 PMID: 29373196 DOI: 10.1016/j.radonc.2017.12.028

163. May JM, Waddle MR, Miller DH, Stross WC, Kaleem TA, May BC, Miller RC, Jiang L, Strong GW, Trifiletti DM, Chaichana KL, Reimer R, Tun HW, Peterson JL. Primary histiocytic sarcoma of the central nervous system: a case report with platelet derived growth factor receptor mutation and PD-L1/PD-L2 expression and literature review. Radiat Oncol. 2018 Sep 5; 13 (1):167 Epub 2018 Sept 05 PMID: 30185195 PMCID: 6126020 DOI: 10.1186/s13014-018-1115-x

164. Matuszak MM, Fuller CD, Yock TI, Hess CB, McNutt T, Jolly S, Gabriel P, Mayo CS, Thor M, Caissie A, Rao A, Owen D, Smith W, Palta J, Kapoor R, Hayman J, Waddle M, Rosenstein B, Miller R, Choi S, Moreno A, Herman J, Feng M. Performance/outcomes data and physician process challenges for practical big data efforts in radiation oncology. Med Phys. 2018 Oct; 45 (10):e811-e819 Epub 2018 Sept 19 PMID: 30229946 DOI: 10.1002/mp.13136

165. Lou Y, Dholaria B, Soyano A, Hodge D, Cochuyt J, Manochakian R, Ko SJ, Thomas M, Johnson MM, Patel NM, Miller RC, Adjei AA, Ailawadhi S. Survival trends among non-small-cell lung


cancer patients over a decade: impact of initial therapy at academic centers. Cancer Med. 2018 Oct; 7 (10):4932-4942 Epub 2018 Sept 02 PMID: 30175515 PMCID: 6198232 DOI: 10.1002/cam4.1749

166. McClelland S 3rd, Kaleem T, Bernard ME, Ahmed HZ, Sio TT, Miller RC. The pervasive crisis of diminishing radiation therapy access for vulnerable populations in the United States-Part 4: Appalachian patients. Adv Radiat Oncol. 2018 Oct-Dec; 3 (4):471-477 Epub 2018 Aug 10 PMID: 30370344 PMCID: 6200890 DOI: 10.1016/j.adro.2018.08.001

167. Mayo CS, Phillips M, McNutt TR, Palta J, Dekker A, Miller RC, Xiao Y, Moran JM, Matuszak MM, Gabriel P, Ayan AS, Prisciandaro J, Thor M, Dixit N, Popple R, Killoran J, Kaleba E, Kantor M, Ruan D, Kapoor R, Kessler ML, Lawrence TS. Treatment data and technical process challenges for practical big data efforts in radiation oncology. Med Phys. 2018 Oct; 45 (10):e793-e810 Epub 2018 Sept 18 PMID: 30226286 DOI: 10.1002/mp.13114

168. Sio TT, Atherton PJ, Pederson LD, Zhen WK, Mutter RW, Garces YI, Ma DJ, Leenstra JL, Rwigema JM, Dakhil S, Bearden JD, van der Veen SJ, Ganti AK, Schild SE, Miller RC. Daily Lisinopril vs Placebo for Prevention of Chemoradiation-Induced Pulmonary Distress in Patients With Lung Cancer (Alliance MC1221): A Pilot Double-Blind Randomized Trial. Int J Radiat Oncol Biol Phys. 2018 Nov 2 Epub 2018 Nov 02 PMID: 30395904 DOI: 10.1016/j.ijrobp.2018.10.035

169. Mattiucci GC, Morganti AG, Cellini F, Buwenge M, Casadei R, Farioli A, Alfieri S, Arcelli A, Bertini F, Calvo FA, Cammelli S, Fuccio L, Giaccherini L, Guido A, Herman JM, Macchia G, Maidment BW 3rd, Miller RC, Minni F, Regine WF, Reni M, Partelli S, Falconi M, Valentini V. Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis. Transl Oncol. 2019 Jan; 12 (1):1-7 Epub 2018 Sept 17 PMID: 30237099 PMCID: 6143718 DOI: 10.1016/j.tranon.2018.08.017

170. Lassen-Ramshad Y, Ozyar E, Alanyali S, Poortmans P, van Houtte P, Sohawon S, Esassolak M, Krengli M, Villa S, Miller R, Demiroz C, Akyurek S, Aggerholm-Pedersen N, Thariat J. Paraganglioma of the head and neck region, treated with radiation therapy, a Rare Cancer Network study. Head Neck. 2019 Jan 11 [Epub ahead of print] PMID: 30633446 DOI: 10.1002/hed.25611

Book chapters

1. Miller RC, Kee AY, Schomas DA, Iott MJ, Bhatia S, Jatoi A. Managing the complications of multimodality therapy. In: Jobe BA; Thomas CR Jr; Hunter JG. Esophageal cancer: principles and practice. New York: Demos Medical; 2009. p. 649-58.

2. Miller RC. Forward; Erdheim-Chester Disease. In: Mirimanoff, Ozsahin. Belkacemi, Management of Adult Rare Tumours 1 ed. France: Springer-Verlag; 2010. p. 3-4; 523-530.

3. Gunderson LL, Haddock MG, Kapp DS, Miller RC, Callister MD, Gottschalk AR. Intraoperative radiation therapy. In:. Hoppe RT; Phillips TL; Roach M, III editors. Leibel and Phillips textbook of radiation oncology. 3rd Edition. Philadelphia: Elsevier/Saunders; 2010. p. 303-28.

4. Miller RC, Gunderson, Valentini, Willett. Pancreas Cancer. In: Gunderson, Willet, Harrison, Calvo. Intraoperative Radiotherapy 3 ed. New Jersey: Humana; 2010.

5. Gill, Brown, Miller RC. Management of Colon Cancer. In: Blanke, Talamonti, Roedel. Gastrointestinal Oncology - Therapeutic Principles 1 ed. Berlin Heidelberg: Springer; 2011.

6. Miller RC. Treatment of Anal Cancer. In: Welton, Thomas. Anal Cancer 1 ed. 2012.7. Alberts SR, Call JA, Hallemeier CL, Miller RC. Adjuvant and neoadjuvant therapy for colorectal

cancer. In:. Yeo CJ editor. Shackelford's surgery of the alimentary tract. 7th Edition. Volume 2. Philadelphia: Elsevier/Saunders; 2013. p. 2199-208.


Abstracts

1. Miller R, Wilson K, Feola JM, Urano M, Yaes RJ, Maruyama Y. Study of whole-body megavoltage grid radiation tolerance. (Abstract 119). Radiology. 1989 Nov; 173(P Suppl):363.

2. Miller RC, Wilson KG, Feola JM, Urano M, Yaes R, Maruyama Y. Total-body-irradiation of c3hf/sed mice with a megavoltage grid: potential for bone marrow transplant therapy. (Abstract 170). Int J Radiat Oncol Biol Phys. 1990; 19(Suppl 1):213.

3. Urano, Majima, Reynolds, Miller RC. Arrhenius analysis in vitro and thermal enhancement ratio (TER) in vivo: Four chemotherapeutic agents given at elevated temperatures. Radiation Research. 1991;1:282.

4. Miller RC, Foote RL, Coffey RJ, Gorman DA, Earle JD, Schomberg PJ, et al. Stereotactic radiosurgery for malignant skull-base tumors. (Abstract 570). Radiology. 1996 Nov; 201(P Suppl):232.

5. Miller RC, Bonner, Kline. The effect of tumor to field edge distance on penumbra in lung tissue. Int J Rad Onc Biol. 1997;39(2):212.

6. Miller RC, Bonner JA, Kline RW. The impact of beam energy and field margin on penumbra at lung tumor-lung parenchyma interfaces. (Abstract 155). Int J Radiat Oncol Biol Phys. 1997; 39(2 Suppl):212.

7. Miller RC, Bonner JA, Wenger DE, Foote RL, Kisrow KL, Shaw EG. Spinal cord localization in the treatment of lung cancer: use of conventional radiographical landmarks. Winner of the Young Oncologist Essay Award, 1997. (Abstract). 79th Annual Meeting of the American Radium Society. New York, NY, 1997 Apr. The Cancer Journal 1997; 3(2):120.

8. Miller RC, Martenson JA, Sargent DJ, Kahn MJ, Krook JE. Acute diarrhea during rectal surgical adjuvant postoperative pelvic radiation therapy (RT) with or without 5-fluorouracil: a detailed analysis of toxicity from a randomized North Central Cancer Treatment Group study. (Abstract 1074). Program/Proceedings of the American Society of Clinical Oncology. 1998; 17:279a.

9. Miller RC, Matteson. Initiation of sphincter sparing treatment for squamous cell carcinoma of the anal canal in a North American community hospital. Radiol Oncol. 2000;34(3):237.

10. Miller R, Foote R, Owens D, Kozelsky T. Improving the quality of care in a rural radiation oncology center through use of telemedicine. Eur J Cancer. 2001 Oct; 37(Suppl 6):S200.

11. Miller R. A proposed curriculum in clinical ethics for radiation oncology resident training. Radiotherapy and Oncology. 2002; 64(1):S155.

12. Albain K, Scott C, Rusch V, Turrisi A, Shepherd F, Smith C, Gandara D, Johnson D, Green M, Miller R. Phase III Comparison of Concurrent Chemotherapy Plus Radiotherapy (CT/RT) and CT/RT Followed by Surgical Resection for Stage IIIA (Pn2) Non-Small Cell Lung Cancer (NSCLC): Initial Results From Intergroup Trial 0139 Proc Am Soc Clin Oncol. 2003; 22:621.

13. Albain KS, Scott CB, Rusch VR, Turrisi AT, Shepherd SA, Smith C, Gandara DR, Johnson D, Green MR, Miller RC. Phase III study of concurrent chemotherapy and full course radiotherapy (CT/RT) versus CT/RT induction followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): first outcome analysis of North American Intergroup trial 0139 (RTOG 93-09) (Abstract PL-4). Lung Cancer. 2003 Aug; 41(Suppl 2):S4.

14. Gines A, Cassivi SD, Martenson JA, Zinsmeister AR, Deschamps C, Allen MS, Quevedo FJ, Sinicrope FA, Murray JA, Schleck C, Alberts SR, Miller RC, Haddock MG, Nichols FC, Vazques-Sequeiros E, Zais T, Romero Y. Impact of endoscopic ultrasonography (EUS) and EUS-fine needle aspiration (FNA) on the management of patients with cancer of the esophagus and gastroesophageal junction. Gastroenterology. 2004; 126(4 Suppl 2): A435.


15. Miller RC, Haddock MG, Petersen IA, Gunderson LL, Further AE. Intraoperative electron beam radiotherapy and human ureteral obstruction (Abstract 2136). Int J Radiat Oncol Biol Phys. 2004; 60(1 Suppl):S415.

16. Albain KS, Swann RS, Rusch VR, Turrisi AT, Shepherd FA, Smith CJ, Gandara DR, Johnson DH, Green MR, Miller RC. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309) (Abstract 7014). J Clin Oncol. 2005 Jun; 23(16S part I):624s.

17. Goldberg H, Miller R, Abdah-Bortnyak R, Shteiner M, Bilboa Y, Villa Freixa S, Mendez A, Azria D, Poortmans P, Kuten A. Outcome after combined modality treatment for uterine papillary serous carcinoma: a rare cancer network (RCN) multicenter study (Abstract 919). EJC. 2005 Oct; 3(2):264-5.

18. * Schallenkamp J, Brinkmann D, Foote T, Garces Y, Miller R. Radiation pneumonitis risk with clinical and dosimetric correlations (Abstract 1144). EJC. 2005 Oct; 3(2):331.

19. Anacak Y, Miller R, Constantinou N, Mamusa A, Ozsahin M, Li Y, Epelbaum R, Lucas A, Kowalcyk A, Bese N, et al. MALT lymphoma of the salivary glands: a multicenter rare cancer network study of 59 patients (Abstract 2522). Int J Radiat Oncol Biol Phys. 2006; 66(3 Suppl):S500.

20. Sarkaria JN, Mladek AC, Schild SE, Miller RC, Garces YI, Grogan PT, Schwingler PM. Phase I trial of thoracic radiation, cisplatin and sirolimus in non-small cell lung cancer and parallel studies of drug effects on radiation pneumonitis in mice (Abstract 2500). Int J Radiat Oncol Biol Phys. 2006; 66(3 Suppl):S488.

21. Furutani KM, Miller RC, McLemore LB, Goulet CC, Brinkmann DH, Haddock MG. 4D CT dosimetric analysis of the Mayo Clinic brachytherapy technique for a cholangiocarcinoma patient (Abstract OR-19). Brachytherapy. 2006 Apr-Jun; 5(2):84.

22. Martenson JA, Sloan JA, Deming DB, Wender DB, Stien KJ, Tai TH, Proulx GM, Zhu AW, Miller RC, Atherton PJ. Phase III double-blind study of depot octreotide versus placebo in the prevention of acute diarrhea during pelvic radiation therapy: Results of North Central Cancer Treatment Group protocol N00CA. (Abstract 8506). J Clin Oncol. 2006 Jun 20; 24(18s):469s.

23. Lachance DH, Miller RC, Lucchinetti CF, Keegan BM, Gavrilova R, Brown PD, Weinshenker BG, Rodriguez M. Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: the Mayo Clinic experience (Abstract RO-17). Neuro-oncol. 2006 Oct; 8(4):487.

24. Weber DC, Miller RC, Taghian A, Hanssens P, Villa S, Ozsahim M, Mirimanoff RO, Nichioka H, Castadot P, Rutz H. Outcome and prognostic factors in cerebellar glioblastoma multiforme in adults: a retrospective study from the rare cancer network (Abstract 2076). Int J Radiat Oncol Biol Phys. 2006 Nov 1; 66(3 Suppl):S252.

25. Corsini MM, Miller RC, Haddock MG, Bhatia S. Prognostic factors and impact of adjuvant radiotherapy and chemotherapy on resected mucinous adenocarcinomas of the pancreas (Abstract 2148). Int J Radiat Oncol Biol Phys. 2006 Nov 1; 66(3 Suppl):S293.

26. Gold DG, Miller RC, Petersen IA. Radiation therapy in patients with scleroderma: the Mayo Clinic experience (Abstract 212). Int J Radiat Oncol Biol Phys. 2006 Nov 1; 66(3 Suppl):S118-9.

27. Gruber G, Omlin A, Amichetti M, Azria D, Fourneret P, Poortmans P, Naehrig D, Miller R, Krengli M, Cole B, et al. Significant benefit of boost irradiation in younger patients with DCIS (Abstract 56). Int J Radiat Oncol Biol Phys. 2006 Nov 1; 66(3 Suppl):S33.

28. Corsini MM, Miller RC, Haddock MG, Donohue JH, Farnell MB, Nagorney DM, Jatoi A, McWilliams RR, Bhatia S, Gunderson LL. Adjuvant radiation and chemotherapy for pancreatic adenocarcinoma: The Mayo clinic experience. Int J Radiat Oncol Biol Phys. 2007; 69(3 Suppl S):S79.


29. Miller RC, Atherton PJ, Kabat B, Fredericksen M, Deschamps C, Jatoi A, Romero Y. Assessment of quality of life in patients with esophageal cancer after combined modality therapy. Int J Radiat Oncol Biol Phys. 2007; 69(3 Suppl S):S584.

30. Schomas DA, Miller RC, Gill S, Thurmes PJ, Haddock MG, Quevedo JF, Donohue JH. Intraperitoneal treatment for peritoneal mucinous carcinomatosis of appendiceal origin after operative management: The Mayo clinic experience. Int J Radiat Oncol Biol Phys. 2007; 69(3 Suppl S):S275-6.

31. Mak K, Miller R, Krishnan S, Laperricre N, Micke O, Rutten I, Kadish S, Ozsahins M, Miruranoft R. Outcomes and prognostic factors in primary intraocular lymphoma: A multicenter rare cancer network study. Int J Radiat Oncol Biol Phys. 2007; 69(3 Suppl S):S534-5.

32. Pirin ME, Gold DG, Petersen IA, Osborn TG, Brown PD, Miller RC. Radiotherapy and systemic lupus erythematosus: The mayo clinic experience. Int J Radiat Oncol Biol Phys. 2007; 69(3 Suppl S):S544-5.

33. Bhatia S, Miszczyk L, Roelandts M, Nguyen T, Boterberg T, Poortmans P, Miller R. Radiotherapy for marginally resected, unresectable, and recurrent giant cell tumors of bone: A Rare Cancer Network study. Int J Radiat Oncol Biol Phys. 2007; 69(3 Suppl S):S753.

34. Gold DG, Miller RC, Pinn ME, Petersen IA, Osborn TG, Brown PD. Risk of late toxicity after radiotherapy in patients with connective tissue disorders: Association with connective tissue disorder severity. Int J Radiat Oncol Biol Phys. 2007; 69(3 Suppl S):S749.

35. Miller RC, Atherton PJ, Kabat BF, Fredericksen MB, Deschamp C, Jatoi A, Geno DM, Romero Y. Changes in quality of life over time in 701 patients with esophageal cancer and Barrett's esophagus based on marital status. Ejc Supplements. 2007 Sep; 5(4):143-4.

36. Atherton PJ, Kabat BF, Miller RC, Romero Y, Fredericksen M, Sloan JA. Changes in quality of life over time in patients registered on the Mayo clinic esophageal adenocarcinoma and Barrett's Esophagus Registry. Am J Gastroenterol. 2007 Sep; 102(Suppl 2):S143.

37. Hsu CC, Herman JM, Corsini MM, Winter JM, Callister MD, Cameron JL, Pawlik TM, Swartz MJ, Gunderson LL, Miller RC. Adjuvant chemoradiation therapy after surgical resection for 1092 cases of pancreatic adenocarcinoma: The Johns Hopkins Hospital - Mayo Clinic collaborative study of pancreatic cancer. Int J Radiat Oncol Biol Phys. 2008; 72(1 Suppl S):S13.

38. Ko S, Corsini MM, Haddock MG, Wallace MB, Kim G, Jatoi A, Gunderson LL, Miller RC. Adverse prognostic factors impacting survival in resected invasive, mucinous cystadenocarcinomas of the pancreas. Int J Radiat Oncol Biol Phys. 2008; 72(1 Suppl S):S249.

39. Herman JM, Hsu C, Zhou J, Bhatia S, Winter J, Haddock M, Donohue J, Pawlik TM, Cameron J, Miller RC. Benefit of adjuvant chemoradiation therapy for ampullary adenocarcinoma: The Johns Hopkins Hospital - Mayo Clinic collaborative study. Int J Radiat Oncol Biol Phys. 2008; 72(1 Suppl S):S126.

40. Macdonald O, Garces YI, Miller J, Kruse JJ, Miller RC, Foote RL. Dose characteristics of proton beam radiotherapy and stereotactic body radiotherapy in primary non-small cell lung carcinoma (NSCLC): A comparative analysis. Int J Radiat Oncol Biol Phys. 2008; 72(1 Suppl S):S618.

41. Haddock MG, Miller RC, Nelson H, Gunderson LL. Intraoperative electron irradiation for locally recurrent colorectal cancer. Int J Radiat Oncol Biol Phys. 2008; 72(1 Suppl S):S70.

42. Schomas DA, Peller PJ, Donahue JM, Nichols FC, Lowe V, Quevedo JF, Miller RC. Positron emission tomography scanning and pathologic assessment of neoadjurvant chemoradiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2008; 72(1 Suppl S):S251-2.

43. Corsini MM, Miller RC, Haddock MG, Gunderson LL. Pre-operative CA 19-9 > 90 is associated with worse overall survival and marginal resection status in resectable, invasive pancreatic carcinoma. Int J Radiat Oncol Biol Phys. 2008; 72(1 Suppl S):S128.


44. Villa S, Miller RC, Krengli M, Abousaris H, Baumert BO, Servagi-Vernat S, Igdem S, Lucas A, Boluda S, Mirimanoff RO. Primary Pineal Tumors; Outcome and prognostic factors: A study from the rare cancer network (RCN). Int J Radiat Oncol Biol Phys. 2008; 72(1 Suppl S):S224.

45. Bhatia S, Miller RC, Quevedo JF, Schomas DA, Haddock MG. Review of treatment outcomes for esophageal cancer: the Mayo Clinic Experience. Int J Radiat Oncol Biol Phys. 2008; 72(1 Suppl S):S250.

46. Weber DC, Miller R, Villa S, Kadish SP, Anacak Y, Abusaris H, Ozygit G, Baumert B, Zaucha R, Pica A. The results of surgery, with or without radiotherapy, for primary spinal myxopapillary ependymoma: A retrospective study from the rare cancer network. Int J Radiat Oncol Biol Phys. 2008; 72(1 Suppl S):S204.

47. Gold D, Miller R, Haddock M, Gunderson L. Adjuvant therapy for gallbladder cancer: the Mayo Clinic experience. American Journal of Clinical Oncology-Cancer Clinical Trials. 2008 Dec; 31(6):614.

48. Ozsahin E, Sozzi WJ, Kallel A, Villette S, Belkacemi Y, Vautravers C, Nguyen T, Miller R, Li YX, Khanfir K. Adenoid cystic carcinoma of the breast: a rare cancer network study. Int J Radiat Oncol Biol Phys. 2009; 75(Suppl S):S184-5.

49. MacDonald OK, Kazemba B, Olivier KR, Brown PD, Miller RC, Fong de Los Santos L, Garces YL. Comparative analysis of coplanar vs. noncoplanar planning approaches in extra-cranial stereotactic radiotherapy (SBRT) of early stage peripheral non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 2009; 75(Suppl S):S686-7.

50. Miller RC, Schwartz DJ, Sloan JA, Griffin PC, Deming RL, Anders JC, Atherton PJ, Loprinzi CL, Burger KN, Martenson JA. Comparison of provider assessed and patient reported outcome measures of acute skin toxicity during a phase III trial of mometasone cream versus placebo during breast RT from the North Central Cancer Treatment Group (N06C4). Int J Radiat Oncol Biol Phys. 2009; 75(Suppl S):S185.

51. Jensen AW, Macdonald OK, Kruse JJ, Miller JM, Miller RC, Haddock MG, Haddock MG, Foote RL. Dosimetric comparison of proton radiotherapy and photon stereotactic body radiotherapy for treatment of liver metastases. Int J Radiat Oncol Biol Phys. 2009; 75(Suppl S):S705.

52. Igdem S, Spiegel D, Efstathiou J, Zietman A, Miller R, Poortmans P, Unsal D. Prostatic duct adenocarcinoma: clinical characteristics, treatment options and outcomes: a rare cancer network study. Int J Radiat Oncol Biol Phys. 2009; 75(Suppl S):S300-1.

53. Barney BM, MacDonald OK, Fong de los Santos LE, Miller RC, Haddock MG. Clinical outcomes and dosimetric considerations using stereotactic body radiotherapy (SBRT) for abdominopelvic tumors. Int J Radiat Oncol Biol Phys. 2010; 78(Suppl S):S313-4.

54. Stauder MC, MacDonald OK, Olivier KR, Miller RC, Brown PD, Garces YI. Early pulmonary toxicity of lung stereotactic body radiation therapy (SBRT) delivered as consecutive daily fractions. Int J Radiat Oncol Biol Phys. 2010; 78(Suppl S):S182-3.

55. Woltman NM, Garces Y, Olivier K, Miller R. Incidence of radiation pneumonitis after thoracic intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2010; 78(Suppl S):S738.

56. Mattiucci G, Valentini V, van Stiphout RGPM, Calvo F, Reni M, Miller RC, Doglietto GB, Alfieri S, Lammering G, Lambin P. Nomograms for the prediction of local control, distant metastases, and survival for pancreas cancer patients. Int J Radiat Oncol Biol Phys. 2010; 78(Suppl S):S101.

57. Atherton P, Burger K, Loprinzi C, Miller R, Jatoi A, Sloan J. Using the Skindex-16 and CTCAE to assess rash symptoms: Results of a pooled-analysis (N0993). J Clin Oncol. 2010 May 20; 28(15s):9018.

58. Hallemeier CL, Iott MJ, Martenson JA, Haddock MG, Miller RC. Circulating interleukin-6 and transforming growth factor-beta levels are not elevated during pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2011; 81(S):S760.


59. Barney BM, Olivier KR, Wilson ZC, Miller RC, Macdonald OK, Brown PD, Foote RL, Markovic SN. Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for stage IV melanoma. Int J Radiat Oncol Biol Phys. 2011; 81(S):S687.

60. Ahmed KA, Stauder MC, Miller RC, Bauer HJ, Olivier KR, Laack NN. Clinical outcomes of single and multifractionated SBRT schedules for spinal metastases. Int J Radiat Oncol Biol Phys. 2011; 81(S):S292-3.

61. Stauder MC, Olivier KR, Macdonald OK, Lafata K, Mayo CS, Bauer HJ, Miller RC, Brown PD, Garces YI. Maximum PTV dose predicts for radiation pneumonitis following lung stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2011; 81(S):S614.

62. Thariat JO, Miller RC, Maingon P, Brouchet A, Thyss A, Ray-Coquard I, Italiano A, Sarini J, Dassonville O, Julieron M. Primary osteosarcomas of the mandible: impact of margins and perioperative management. Int J Radiat Oncol Biol Phys. 2011; 81(S):S484.

63. Barney B, Olivier K, Miller R, Fong de los Santos L, Haddock M. Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for non-liver abdominal cavity tumors. American Journal Of Clinical Oncology-cancer Clinical Trials. 2011 Apr; 34(2):196.

64. Khwaja S, Barney B, Olivier K, Miller R, Haddock M. Clinical outcomes using stereotactic body radiation therapy (SBRT) for metastases to retroperitoneal lymph nodes. American Journal Of Clinical Oncology-cancer Clinical Trials. 2011 Apr; 34(2):206.

65. Call J, Haddock M, Quevedo JF, David L, Miller R. Concurrent chemotherapy and intensity modulated radiation therapy (IMRT) in the treatment of anal cancer: a retrospective review from a large academic center. American Journal Of Clinical Oncology-cancer Clinical Trials. 2011 Apr; 34(2):199.

66. Atherton PJ, Halyard MY, Sloan JA, Miller RC, Deming RL, Tai THP, Stien KJ, Martenson JA. Patient Assessment of Measures of Bowel Function During and After Pelvic Radiation Therapy: An Ancillary Study of NCCTG Study N00CA. J Clin Oncol. 2012; 30(suppl; abstr e1657).

67. Abu Dayyeh BK, Vandamme JJ, Miller RC, Baron TH. Esophageal self-expandable metal stents material and mesh grid density are the biggest determinants of radiation dose enhancement in the setting of esophageal radiotherapy. Gastrointest Endosc. 2012 Apr; 75(4):458.

68. Hallemeier C, Stauder M, Miller R, Garces Y, Foote R, Bauer H, Lafata K, Mayo C, Olivier K. Lung stereotactic body radiotherapy using coplanar versus non-coplanar beam arrangements: a comparison of clinical outcomes. American Journal Of Clinical Oncology-cancer Clinical Trials. 2012 Apr; 35(2):201.

69. Weber DC, Li J, Miller R, Villa S, Anacak Y, Poortmans P, Baumert B, Pica A, Ozyigit G, Preusser M. Outcome of patients with primary spinal myxopapillary ependymoma: a retrospective study from the md anderson cancer center and rare cancer network. Neuro-oncol. 2012 Sep; 14:72.

70. Barney BM, Haddock MG, Miller RC, Olivier KR. Clinical outcomes and toxicity using stereotactic body radiation therapy (sbrt) for advanced cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2012 Nov 1; 84(3):S325.

71. Blanchard MJ, Brown LC, Miller RC, Stafford SL, Laack NN. Evaluation of limited-volume involved-nodal radiation therapy (in) and intensity modulated radiation therapy (imrt) in the treatment of Hodgkin lymphoma (hl). Int J Radiat Oncol Biol Phys. 2012 Nov 1; 84(3):S613.

72. Miller RC, Leenstra J, Qun R, Martenson JA, Dornfeld KJ, Bearden JD, Puri D, Stella PJ, Foote RL, Loprinzi CL. N09c6 (alliance) - a phase 3, randomized double-blind study of doxepin rinse versus placebo in the treatment of acute oral mucositis pain in patients receiving head and neck radiation therapy with or without chemotherapy International Journal Of Radiation Oncology Biology Physics. 2013 Jan 1; 85: (1)21.

73. Alberts SR, Soori GS, Shi Q, Wigle D, Sticca RP, Miller RC, Leenstra JL, Peller PJ, Wu TT, Yoon H, Drevyanko TF, Ko SJ, Mattar BI, Nikcevich DA, Behrens RJ, Khalil MF, Kim GP. Randomized Phase


II trial of extended versus standard neoadjuvant therapy for esophageal cancer, NCCTG clinical trial N0849. J Clin Oncol. 2013; 31. Abstract no. 4026.

74. Miller R, Gross M, Jhawar S, Madkhali S, Miller R. Content analysis of social media traffic related to the 2012 eortc-nci-aacr symposium on molecular targets and cancer therapeutics. Eur J Cancer. 2013 Sep; 49:S335.

75. Miller R, Leenstra J, Qin R, Martenson J, Dornfeld K, Bearden J, Puri D, Stella P, Foote R, Loprinzi C. N09c6 (alliance) - a phase iii, randomized double-blind study of doxepin rinse versus placebo in the treatment of acute oral mucositis pain: secondary analysis of the continuation phase European Journal Of Cancer. 2013 Sep; 49:S759.

76. Merrell K, Hallemeier C, Quevedo F, Kendrick M, Haddock M, Miller R. Outcomes and prognostic factors following r1 and r2 resection of non-metastatic pancreas cancer. Eur J Cancer. 2013 Sep; 49:S584.

77. Merrell KW, Barney BM, Park SS, Laack NN, Haddock MG, Miller RC, Olivier KR. An institutional review of stereotactic body radiation therapy for liver tumors. Int J Radiat Oncol Biol Phys. 2013 Oct 1; 87(2):S322-3.

78. Sio TT, Liang JJ, Novotny PJ, Lennon RJ, Prasad A, Miller RC. Dosimetric correlate of cancer and cardiac-specific survival in 231 patients who received both external beam radiation therapy (ebrt) and percutaneous coronary intervention. Int J Radiat Oncol Biol Phys. 2013 Oct 1; 87(2):S573.

79. Thariat JO, Sio T, Barsela G, Novotny PJ, Sun X, Miller RC. External beam radiation therapy experience in nonanaplastic thyroid carcinoma: a rare cancer network study. Int J Radiat Oncol Biol Phys. 2013 Oct 1; 87(2):S461-2.

80. Sio TT, Anderson BW, Liu H, Ginos BF, Romero Y, Jatoi A, Deschamps C, Sloan JA, Miller RC. Initial quality-of-life deficit in patient-reported outcome is related to cancer stage: a single institution esophageal adenocarcinoma registry study. Int J Radiat Oncol Biol Phys. 2013 Oct 1; 87(2):S133-4.

81. Sio TT, Schwartz DJ, Atherton PJ, Neben Wittich, Griffin PC, Martenson JA, Sloan JA, Morton RF, Loprinzi CL, Miller RC. Repeated measure analysis of dermatitis symptoms evolution and patient-reported outcome in n06c4: a phase 3 randomized trial of mometasone furoate in breast cancer patients receiving radiation therapy. Int J Radiat Oncol Biol Phys. 2013 Oct 1; 87(2):S116-7.

82. Sio TT, Beltran CJ, Ashman JB, Wurgler SK, Hoeft KA, Miller RC. Scanning beam stereotactic body proton therapy (sbpt) for pancreatic cancer: a dosimetric feasibility study. Int J Radiat Oncol Biol Phys. 2013 Oct 1; 87(2):S185.

83. Liang JJ, Sio TT, Slusser JP, Lennon RJ, Miller RC, Prasad A. Impact of curative thoracic radiation therapy for cancer in patients with coronary artery stents. Circulation. 2013 Nov 26; 128(22).

84. Liang JJ, Sio TT, Slusser JP, Lennon RJ, Miller RC, Prasad A. Outcomes following percutaneous coronary intervention in cancer survivors previously treated with thoracic radiation therapy. Circulation. 2013 Nov 26; 128(22).

85. Miller RC, Petereit DG, Sloan JA, Liu H, Martenson JA, Bearden JD, Sapiente R, Seeger GR, Iott MJ, Loprinzi CL. N08C9 (Alliance) - A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy. Int J Radiat Oncol Biol Phys. 2013 Dec 1; 87(5):1186-7. Epub 2013 Nov 20

86. Anderson BW, Sio TTW, Liu HS, Ginos BF, Romero Y, Jatoi A, Deschamps C, Sloan JA, Miller RC. Relationship of initial quality-of-life deficit and survival in esophageal cancer (ec): the Mayo Clinic Romero registry experience. J Clin Oncol. 2014 Jan 20; 32(3).

87. Anderson BW, Chang K, Funk RK, Sio TT, Molina JR, Miller RC. A comprehensive genome-based mutational analysis by next generation sequencing in 22 consecutive patients with thoracic malignancies. Int J Radiat Oncol Biol Phys. 2014 Sep 1; 90:S102-3.


88. Sio TT, Tryggestad EJ, Ashman JB, Beltran CJ, Harmsen WS, Hoeft KA, Wurgler SK, Miller RC. A dosimetric planning feasibility study for spot-scanned stereotactic body proton therapy (sbpt) for unresectable pancreatic tumors. Int J Radiat Oncol Biol Phys. 2014 Sep 1; 90:S917-8.

89. Tryggestad EJ, Sio TT, Ashman JB, Beltran CJ, Whitaker TJ, Hoeft KA, Wurgler SK, Miller RC. Aggregated plan robustness analyses for spot-scanned pancreatic stereotactic body proton therapy. Int J Radiat Oncol Biol Phys. 2014 Sep 1; 90:S918.

90. Sio TT, Liu H, Ginos BF, Anderson BW, Romero Y, Jatoi A, Deschamps C, Sloan JA, Miller RC. Initial quality of life (qol) deficit is related to decreased survival in esophageal cancer (ec): final report of 840 consecutive patients prospectively evaluated by the single-institutional romero registry. Int J Radiat Oncol Biol Phys. 2014 Sep 1; 90:S85.

91. Merrell KW, Hallemeier CL, Quevedo F, Kendrick ML, Haddock MG, Miller RC. Outcomes and prognostic factors in patients receiving adjuvant therapy for resected exocrine pancreas cancer. Int J Radiat Oncol Biol Phys. 2014 Sep 1; 90:S50.

92. James SE, Sio TT, Graham RP, Keeney MG, Chang K, Miller RC. Potential presurgical predictors for pathologic response in patients with advanced esophageal carcinoma treated with trimodality therapy. Int J Radiat Oncol Biol Phys. 2014 Sep 1; 90:S347-8.

93. Miller RC, Petereit DG, Sloan JA, Liu H, Martenson JA, Bearden JD, Sapiente R, Seeger GR, Mowat RB, Liem B, Iott MJ, Loprinzi CL. Primary and secondary endpoint analysis of n08c9 (alliance): a phase 3 randomized trial of sulfasalazine versus placebo in the prevention of acute radiation enteritis. Int J Radiat Oncol Biol Phys. 2014 Sep 1; 90:S86.

94. Chang K, James SE, Merrell KW, Sio TT, Lester SC, Patel AB, Cai Y, Miller RC. Radiation toxicity in patients with scleroderma, discoid, and systemic lupus erythematosus: a retrospective 26-year single-institutional study. Int J Radiat Oncol Biol Phys. 2014 Sep 1; 90:S686.

95. Anand A, Bues M, Haddock MG, William RG, Beltran C, Liu W, Hallemeier CL, Keole SR, Miller RC, Ashman JB. Robust scanned proton treatment plans provide large reductions in bone marrow exposure for pelvic radiation therapy for anal cancer. Int J Radiat Oncol Biol Phys. 2014 Sep 1; 90:S396.

96. Sio TT, Shah ND, Swanson KM, Inselman JW, Ashman JB, Kreofsky CR, Chang K, Buchholtz LM, Baker MB, Miller RC. Temporal and geographic variation of intensity modulated radiation therapy (imrt) utilization in patients with colorectal cancer: a seer-medicare based analysis. Int J Radiat Oncol Biol Phys. 2014 Sep 1; 90:S580-1.

97. Miller RC, Van Houten H, Foote RL, Keole S, Schild SE, Laack NN, Childs SK, Daniels TB, Crown WH, Shah ND. Understanding the characteristics and types of adult and pediatric cancers treated with proton beam radiation therapy in a population of 88 million commercially insured patients. Int J Radiat Oncol Biol Phys. 2014 Sep 1; 90:S64.

98. Graham RP, Keeney MG, Chang K, James SE, Sio TT, Sakai Y, Zhang L, Miller RC, Oliveira AM, Kipp BR, Halling KC, Sukov WR. Fgfr1 locus amplification is found in a subset of esophageal squamous cell carcinomas. J Mol Diagn. 2014 Nov; 16(6):751-2.

99. Anderson BW, Chang K, Funk RK, Sio TT, Molina JR, Miller RC. A comprehensive genome-based mutational analysis by next generation sequencing in 22 consecutive patients with thoracic malignancies. Int J Radiat Oncol Biol Phys. 2014 Nov 15; 90:S73-4.

Major invited speeches

National


1. Plenary Session, Annual meeting 2012, Boston, MA, “N09C6 (Alliance) - A Phase 3, Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Head and Neck Radiation Therapy With or Without Chemotherapy.”

2. Clinical Trials Session, ASTRO Annual meeting 2013, Atlanta, GA, “Primary and Secondary Endpoint Analysis of N08C9 (Alliance): A Phase 3 Randomized Trial of Sulfasalazine Versus Placebo in the Prevention of Acute Radiation Enteritis.”

3. Clinical Trials Session, ASTRO Annual meeting 2016, Boston, MA, "A Phase III, Randomized Double-Blind Study of Doxepin Rinse Versus “Magic Mouthwash” Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Head and Neck Radiotherapy with or without Chemotherapy (Alliance A221304)."

4. Late Breaking Abstract, ASTRO Annual meeting 2008, “Phase III Randomized Double-Blind Study of Mometasone Furoate versus Placebo in the Prevention of Radiation Dermatitis in Breast Cancer Patients Receiving Radiation Therapy.”

5. Late Breaking Abstract, ASTRO Annual meeting 2017, “Cost of Acute and Follow up Care in Patients with Pre-Existing Psychiatric Diagnoses Undergoing Radiation Therapy.” (Presented by MCF PGY III Mark Waddle)


· Web viewOzyar E, Selek U, Laskar S, Uzel O, Anacak Y, Ben-Arush M, Polychronopoulou S, Akman F,...

Documents

Transcript of · Web viewOzyar E, Selek U, Laskar S, Uzel O, Anacak Y, Ben-Arush M, Polychronopoulou S, Akman F,...